Turning Point Brands, Inc. - Quarter Report: 2022 June (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☑ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2022
or
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _______________ to _______________
Commission file number: 001-37763
TURNING POINT BRANDS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
20-0709285
|
|
(State or other jurisdiction of Incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
5201 Interchange Way,
Louisville, KY
|
40229
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(502) 778-4421
(Registrant’s telephone number, including area code)
Former name, former address and former fiscal year, if changed since last report: not applicable
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
TPB
|
New York Stock Exchange
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
Accelerated filer
|
☑
|
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☐
|
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
At July 19, 2022, there were 17,837,402
shares outstanding of the registrant’s voting common stock, par value $0.01 per share.
Page No.
|
|||
PART I—FINANCIAL INFORMATION
|
|||
ITEM 1
|
Financial Statements (Unaudited)
|
||
Consolidated Statements of Income for the six months ended June 30, 2022 and 2021 | 7 |
||
11 |
|||
ITEM 2
|
|||
ITEM 3
|
48 | ||
ITEM 4
|
48 | ||
PART II—OTHER INFORMATION
|
|||
ITEM 1
|
49 |
||
ITEM 1A
|
49 |
||
ITEM 2
|
49 | ||
ITEM 3
|
49 | ||
ITEM 4
|
49 | ||
ITEM 5
|
49 | ||
ITEM 6
|
50 | ||
51 |
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal
securities laws. Forward-looking statements may generally be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” and “will” or, in each case, their negative, or other variations or comparable terminology.
These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, and depend on circumstances, that may or may not occur
in the future. As a result, actual events may differ materially from those expressed in, or suggested by, the forward-looking statements. Any forward-looking statement made by Turning Point Brands, Inc. (“TPB”), in this Quarterly Report on Form
10-Q speaks only as of the date hereof. New risks and uncertainties arise from time to time, and it is impossible for TPB to predict these events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking
statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to:
● |
declining sales of tobacco products, and expected continuing decline of sales, in the tobacco industry overall;
|
● |
our dependence on a small number of third-party suppliers and producers;
|
● |
the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption,
as well as other supply chain concerns, including delays in product shipments and increases in freight cost;
|
● |
the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted;
|
● |
failure to maintain consumer brand recognition and loyalty of our customers;
|
● |
our reliance on relationships with several large retailers and national chains for distribution of our products;
|
● |
intense competition and our ability to compete effectively;
|
● |
competition from illicit sources and the damage caused by illicit products to brand equity;
|
● |
contamination of our tobacco supply or products;
|
● |
uncertainty and continued evolution of the markets for our NewGen and cigar products;
|
● |
complications with the design or implementation of our new enterprise resource planning system could adversely impact our business and
operations;
|
● |
substantial and increasing U.S. regulation;
|
● |
regulation or marketing denials of our products by the FDA, which has broad regulatory powers;
|
● |
many of our products contain nicotine, which is considered to be a highly addictive substance;
|
● |
requirement to maintain compliance with master settlement escrow agreement;
|
● |
possible significant increases in federal, state and local municipal tobacco- and vapor-related taxes;
|
● |
our products are subject to developing and unpredictable regulation, such as court actions that impact obligations;
|
● |
increase in state and local regulation of our NewGen products has been proposed or enacted;
|
● |
increase in tax of our NewGen products could adversely affect our business;
|
● |
sensitivity of end-customers to increased sales taxes and economic conditions including significant increases in the rate of inflation and other
declines in purchasing power;
|
● |
possible increasing international control and regulation;
|
● |
failure to comply with environmental, health and safety regulations;
|
● |
imposition of significant tariffs on imports into the U.S.;
|
● |
the scientific community’s lack of information regarding the long-term health effects of certain substances contained in some of our products;
|
● |
significant product liability litigation;
|
● |
the effect of the COVID-19 pandemic on our business;
|
● |
our amount of indebtedness;
|
● |
the terms of our indebtedness, which may restrict our current and future operations;
|
● |
identification of a material weakness in our internal control related to ineffective information technology general controls which, if not
remediated appropriately or timely, could result in loss of investor confidence and adversely impact our stock price;
|
● |
Changes in the method for determining LIBOR or the replacement of LIBOR with an alternative reference rate, may adversely affect interest
expense related to outstanding debt;
|
● |
our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or
merger proposals, which may adversely affect the market price of our common stock;
|
● |
our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors. These restrictions may
affect the liquidity of our common stock and may result in Restricted Investors (as defined in our Certificate of Incorporation) being required to sell or redeem their shares at a loss or relinquish their voting, dividend and
distribution rights;
|
● |
future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of
equity or convertible securities may dilute your ownership in us;
|
● |
we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock;
|
● |
our business may be damaged by events outside of our suppliers’ control, such as the impact of epidemics (e.g., coronavirus), political
upheavals, or natural disasters;
|
● |
our reliance on information technology;
|
● |
cybersecurity and privacy breaches;
|
● |
failure to manage our growth;
|
● |
failure to successfully integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions;
|
● |
fluctuations in our results;
|
● |
exchange rate fluctuations;
|
● |
adverse U.S. and global economic conditions;
|
● |
departure of key management personnel or our inability to attract and retain talent;
|
● |
infringement on or misappropriation of our intellectual property;
|
● |
third-party claims that we infringe on their intellectual property; and
|
● |
failure to meet expectations relating to environmental, social and governance factors.
|
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated
Balance Sheets
(dollars in thousands except share data)
ASSETS
|
(unaudited)
June 30,
2022
|
December 31,
2021
|
||||||
Current assets:
|
||||||||
Cash
|
$
|
107,429
|
$
|
128,320
|
||||
Accounts receivable, net of allowances of $161 in 2022 and $262 in 2021
|
9,177
|
6,496
|
||||||
Inventories
|
115,129
|
87,607
|
||||||
Other current assets
|
27,353
|
26,746
|
||||||
Total current assets
|
259,088
|
249,169
|
||||||
Property, plant, and equipment, net
|
22,376
|
18,650
|
||||||
Deferred income taxes
|
2,111
|
1,363
|
||||||
Right of use assets
|
13,749
|
15,053
|
||||||
Deferred financing costs, net
|
335
|
388
|
||||||
Goodwill
|
162,385
|
162,333
|
||||||
Other intangible assets, net
|
86,566
|
87,485
|
||||||
Master Settlement Agreement (MSA) escrow deposits
|
29,224
|
31,720
|
||||||
Other assets
|
28,475
|
35,399
|
||||||
Total assets
|
$
|
604,309
|
$
|
601,560
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
14,436
|
$
|
7,361
|
||||
Accrued liabilities
|
34,560
|
32,937
|
||||||
Other current liabilities
|
38
|
38
|
||||||
Total current liabilities
|
49,034
|
40,336
|
||||||
Notes payable and long-term debt
|
415,410
|
414,172
|
||||||
Lease liabilities
|
11,934
|
13,336
|
||||||
Total liabilities
|
476,378
|
467,844
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding
shares -0-
|
-
|
-
|
||||||
Common stock, voting, $0.01 par value; authorized
shares, 190,000,000; 19,797,735 issued shares and 17,890,441 outstanding shares at June 30, 2022, and 19,690,884
issued shares and 18,395,476 outstanding shares at December 31, 2021
|
198
|
197
|
||||||
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and
outstanding shares -0-
|
-
|
-
|
||||||
Additional paid-in capital
|
110,563
|
108,811
|
||||||
Cost of repurchased common
stock (1,907,294 shares
at June 30, 2022, and 1,295,408
shares at December 31, 2021)
|
(68,287
|
)
|
(48,869
|
)
|
||||
Accumulated other comprehensive loss
|
(2,064
|
)
|
(195
|
)
|
||||
Accumulated earnings
|
85,641
|
71,460
|
||||||
Non-controlling interest
|
1,880
|
2,312
|
||||||
Total stockholders’ equity
|
127,931
|
133,716
|
||||||
Total liabilities and stockholders’ equity
|
$
|
604,309
|
$
|
601,560
|
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Income
(dollars in thousands except share data)
(unaudited)
Three Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Net sales
|
$
|
102,925
|
$
|
122,643
|
||||
Cost of sales
|
51,456
|
62,670
|
||||||
Gross profit
|
51,469
|
59,973
|
||||||
Selling, general, and administrative expenses
|
33,323
|
35,094
|
||||||
Operating income
|
18,146
|
24,879
|
||||||
Interest expense, net
|
5,144
|
5,522
|
||||||
Investment loss (income)
|
6,227
|
(110
|
)
|
|||||
Income before income taxes
|
6,775
|
19,467
|
||||||
Income tax expense
|
1,569
|
4,424
|
||||||
Consolidated net income
|
5,206
|
15,043
|
||||||
Net loss attributable to non-controlling interest
|
(218
|
)
|
(312
|
)
|
||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
||||
Basic income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.30
|
$
|
0.81
|
||||
Diluted income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.30
|
$
|
0.73
|
||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
18,063,259
|
18,975,522
|
||||||
Diluted
|
21,443,279
|
22,489,662
|
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of
Income
(dollars in thousands except share data)
(unaudited)
Six
Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Net sales
|
$
|
203,819
|
$
|
230,284
|
||||
Cost of sales
|
100,556
|
117,050
|
||||||
Gross profit
|
103,263
|
113,234
|
||||||
Selling, general, and administrative expenses
|
65,888
|
64,006
|
||||||
Operating income
|
37,375
|
49,228
|
||||||
Interest expense, net
|
10,340
|
10,009
|
||||||
Investment loss (income)
|
6,149
|
(135
|
)
|
|||||
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
Income before income taxes
|
20,886
|
33,648
|
||||||
Income tax expense
|
4,909
|
7,078
|
||||||
Consolidated net income
|
15,977
|
26,570
|
||||||
Net loss attributable to non-controlling interest
|
(445
|
)
|
(567
|
)
|
||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
16,422
|
$
|
27,137
|
||||
Basic income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.90
|
$
|
1.43
|
||||
Diluted income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.86
|
$
|
1.30
|
||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
18,159,940
|
19,034,415
|
||||||
Diluted
|
21,603,113
|
22,559,087
|
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of
Comprehensive Income
(dollars in thousands)
(unaudited)
Three Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Consolidated net income
|
$
|
5,206
|
$
|
15,043
|
||||
Other comprehensive income (loss), net of tax
|
||||||||
Unrealized (loss) gain on MSA investments, net of tax of $244 in 2022 and $83 in 2021
|
(768
|
)
|
260
|
|||||
Foreign currency translation, net
of tax of $0 in 2022 and 2021
|
45
|
642
|
||||||
Unrealized gain on derivative instruments, net of tax of $0 in 2022 and $126 in 2021
|
-
|
178
|
||||||
(723
|
)
|
1,080
|
||||||
Consolidated comprehensive income
|
4,483
|
16,123
|
||||||
Comprehensive income (loss) attributable to non-controlling interest
|
(203
|
)
|
9
|
|||||
Comprehensive income attributable to Turning Point Brands, Inc.
|
$
|
4,686
|
$
|
16,114
|
Six
Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Consolidated net income
|
$
|
15,977
|
$
|
26,570
|
||||
Other comprehensive income (loss), net of tax
|
||||||||
Unrealized loss on MSA
investments, net of tax of $602 in 2022 and $61 in 2021
|
(1,894
|
)
|
(192
|
)
|
||||
Foreign currency translation, net
of tax of $0 in 2022 and 2021
|
38
|
960
|
||||||
Unrealized gain on
derivative instruments, net of tax of $0 in 2022 and $810 in 2021
|
-
|
2,626
|
||||||
(1,856
|
)
|
3,394
|
||||||
Consolidated comprehensive income
|
14,121
|
29,964
|
||||||
Comprehensive loss attributable to non-controlling interest
|
(432
|
)
|
(87
|
)
|
||||
Comprehensive income attributable to Turning Point Brands, Inc.
|
$
|
14,553
|
$
|
30,051
|
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of
Cash Flows
(dollars in thousands)
(unaudited)
Six
Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Cash flows from operating activities:
|
||||||||
Consolidated net income
|
$
|
15,977
|
$
|
26,570
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
Gain on sale of property, plant, and equipment
|
(8
|
)
|
(2
|
)
|
||||
Depreciation expense
|
1,750
|
1,546
|
||||||
Amortization of other intangible assets
|
919
|
954
|
||||||
Amortization of deferred financing costs
|
1,291
|
1,251
|
||||||
Deferred income tax (benefit) expense
|
(146
|
)
|
1,027
|
|||||
Stock compensation expense
|
2,661
|
4,263
|
||||||
Noncash lease income
|
(6
|
)
|
(19
|
)
|
||||
Loss (gain) on investments
|
6,258
|
(34
|
)
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(2,673
|
)
|
3,955
|
|||||
Inventories
|
(27,499
|
)
|
(12,007
|
)
|
||||
Other current assets
|
(598
|
)
|
813
|
|||||
Other assets
|
624
|
599
|
||||||
Accounts payable
|
7,240
|
1,423
|
||||||
Accrued liabilities and other
|
1,359
|
1,370
|
||||||
Net cash provided by operating activities
|
$
|
7,149
|
$
|
37,415
|
||||
Cash flows from investing activities:
|
||||||||
Capital expenditures
|
$
|
(5,694
|
)
|
$
|
(2,170
|
)
|
||
Acquisitions, net of cash acquired
|
- | (3,419 | ) | |||||
Payments for investments
|
- | (8,657 | ) | |||||
Restricted cash, MSA escrow deposits
|
(10,078
|
)
|
(20,147
|
)
|
||||
Proceeds on the sale of property, plant and equipment
|
63
|
2
|
||||||
Net cash used in investing activities
|
$
|
(15,709
|
)
|
$
|
(34,391
|
)
|
||
Cash flows from financing activities:
|
||||||||
Proceeds from Senior Secured Notes
|
$
|
-
|
$
|
250,000
|
||||
Payments of 2018 first lien term loan
|
-
|
(130,000
|
)
|
|||||
Settlement of interest rate swaps
|
-
|
(3,573
|
)
|
|||||
Payment of dividends
|
(2,181
|
)
|
(2,006
|
)
|
||||
Payments of financing costs
|
-
|
(6,921
|
)
|
|||||
Exercise of options
|
475
|
886
|
||||||
Redemption of options
|
(155
|
)
|
(2,111
|
)
|
||||
Redemption of performance restricted stock units
|
(1,228 | ) | - | |||||
Common stock repurchased
|
(19,418
|
)
|
(14,086
|
)
|
||||
Net cash provided by (used in) financing activities
|
$
|
(22,507
|
)
|
$
|
92,189
|
|||
Net (decrease) increase in cash
|
$
|
(31,067
|
)
|
$
|
95,213
|
|||
Effect of foreign currency translation on cash
|
$
|
56
|
$
|
315
|
||||
Cash, beginning of period:
|
||||||||
Unrestricted
|
128,320
|
41,765
|
||||||
Restricted
|
15,155
|
35,074
|
||||||
Total cash at beginning of period
|
143,475
|
76,839
|
||||||
Cash, end of period:
|
||||||||
Unrestricted
|
107,429
|
157,474
|
||||||
Restricted
|
5,035
|
14,893
|
||||||
Total cash at end of period
|
$
|
112,464
|
$
|
172,367
|
||||
Supplemental schedule of noncash investing activities:
|
||||||||
Accrued capital expenditures
|
$
|
19
|
$
|
242
|
||||
Supplemental schedule of noncash financing activities:
|
||||||||
Dividends declared not paid
|
$
|
1,110
|
$
|
1,241
|
||||
Accrued consideration for acquisition
|
$
|
-
|
$
|
402
|
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Changes in Stockholders’ Equity
For the Three Months Ended June 30, 2022 and 2021
(dollars in thousands except share data)
(unaudited)
Accumulated | ||||||||||||||||||||||||||||||||
Common | Additional | Cost of |
Other | Non- | ||||||||||||||||||||||||||||
Voting | Stock, | Paid-In | Repurchased |
Comprehensive | Accumulated | Controlling | ||||||||||||||||||||||||||
Shares
|
Voting
|
Capital
|
Common Stock
|
Income (Loss)
|
Earnings
|
Interest
|
Total
|
|||||||||||||||||||||||||
Beginning balance April 1, 2022
|
18,180,174
|
$
|
198
|
$
|
109,073
|
$
|
(59,491
|
)
|
$
|
(1,326
|
)
|
$
|
81,327
|
$
|
2,083
|
$
|
131,864
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $244
|
-
|
-
|
-
|
-
|
(768
|
)
|
-
|
-
|
(768
|
)
|
||||||||||||||||||||||
Foreign currency translation, net of tax of $0
|
-
|
-
|
-
|
-
|
30
|
-
|
15
|
45
|
||||||||||||||||||||||||
Stock compensation expense
|
-
|
-
|
1,502
|
-
|
-
|
-
|
-
|
1,502
|
||||||||||||||||||||||||
Exercise of options
|
7,175
|
-
|
230
|
-
|
-
|
-
|
-
|
230
|
||||||||||||||||||||||||
Redemption of options |
- | - | (155 | ) | - |
-
|
-
|
- | (155 | ) | ||||||||||||||||||||||
Performance restricted stock units issuance
|
4,754 | - | - | - | - | - | - | - | ||||||||||||||||||||||||
Redemption of restricted stock units
|
- | - | (87 | ) | - | - | - | - | (87 | ) | ||||||||||||||||||||||
Cost of repurchased common stock
|
(301,662
|
)
|
-
|
-
|
(8,796
|
)
|
-
|
-
|
-
|
(8,796
|
)
|
|||||||||||||||||||||
Dividends
|
-
|
-
|
-
|
-
|
-
|
(1,110
|
)
|
-
|
(1,110
|
)
|
||||||||||||||||||||||
Net income
|
-
|
-
|
-
|
-
|
-
|
5,424
|
(218
|
)
|
5,206
|
|||||||||||||||||||||||
Ending balance June 30, 2022
|
17,890,441
|
$
|
198
|
$
|
110,563
|
$
|
(68,287
|
)
|
$
|
(2,064
|
)
|
$
|
85,641
|
$
|
1,880
|
$
|
127,931
|
|||||||||||||||
Beginning balance April 1, 2021
|
19,059,120
|
$
|
196
|
$
|
102,879
|
$
|
(15,924
|
)
|
$
|
(480
|
)
|
$
|
34,357
|
$
|
3,954
|
$
|
124,982
|
|||||||||||||||
Unrealized gain on MSA investments, net of tax of $83
|
- | - | - | - | 260 | - | - | 260 | ||||||||||||||||||||||||
Unrealized gain on derivative instruments, net of tax of $126
|
-
|
-
|
-
|
-
|
178
|
-
|
-
|
178
|
||||||||||||||||||||||||
Foreign currency translation, net of tax of $0
|
- | - | - | - | 321 | - | 321 | 642 | ||||||||||||||||||||||||
Stock compensation expense
|
-
|
-
|
2,764
|
-
|
-
|
-
|
-
|
2,764
|
||||||||||||||||||||||||
Exercise of options
|
39,403
|
-
|
462
|
-
|
-
|
-
|
-
|
462
|
||||||||||||||||||||||||
Redemption of options |
- | - | (645 | ) | - | - | - | - | (645 | ) | ||||||||||||||||||||||
Cost of repurchased common stock
|
(175,000
|
)
|
-
|
-
|
(8,353
|
)
|
-
|
-
|
-
|
(8,353
|
)
|
|||||||||||||||||||||
Dividends
|
-
|
-
|
-
|
-
|
-
|
(1,065
|
)
|
-
|
(1,065
|
)
|
||||||||||||||||||||||
Net income
|
-
|
-
|
-
|
-
|
-
|
15,355
|
(312
|
)
|
15,043
|
|||||||||||||||||||||||
Ending balance June 30, 2021
|
18,923,523
|
$
|
196
|
$
|
105,460
|
$
|
(24,277
|
)
|
$
|
279
|
$
|
48,647
|
$
|
3,963
|
$
|
134,268
|
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Changes in Stockholders’ Equity
For the Six Months Ended June 30, 2022 and 2021
(dollars in thousands except share data)
(unaudited)
Accumulated | ||||||||||||||||||||||||||||||||
Common | Additional |
Cost of |
Other | Non- | ||||||||||||||||||||||||||||
Voting | Stock, | Paid-In | Repurchased |
Comprehensive | Accumulated | Controlling | ||||||||||||||||||||||||||
Shares
|
Voting
|
Capital
|
Common Stock
|
Income (Loss)
|
Earnings
|
Interest
|
Total
|
|||||||||||||||||||||||||
Beginning balance January 1, 2022
|
18,395,476
|
$
|
197
|
$
|
108,811
|
$
|
(48,869
|
)
|
$
|
(195
|
)
|
$
|
71,460
|
$
|
2,312
|
$ |
133,716
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $602
|
-
|
- | - | - |
(1,894
|
)
|
-
|
-
|
(1,894
|
)
|
||||||||||||||||||||||
Foreign currency translation, net of tax of $0
|
-
|
-
|
-
|
-
|
25
|
-
|
13
|
38
|
||||||||||||||||||||||||
Stock compensation expense
|
-
|
-
|
2,661
|
-
|
-
|
-
|
-
|
2,661
|
||||||||||||||||||||||||
Exercise of options
|
32,341
|
-
|
475
|
-
|
-
|
-
|
-
|
475
|
||||||||||||||||||||||||
Redemption of options
|
-
|
-
|
(155
|
)
|
-
|
-
|
-
|
-
|
(155
|
)
|
||||||||||||||||||||||
Issuance of performance restricted stock units
|
74,510
|
1 | (1 | ) | - | - | - | - | - | |||||||||||||||||||||||
Redemption of performance restricted stock units
|
- | - | (1,141 | ) | - | - | - | - | (1,141 | ) | ||||||||||||||||||||||
Redemption of restricted stock units
|
- | - | (87 | ) | - | - | - | - | (87 | ) | ||||||||||||||||||||||
Cost of repurchased common stock
|
(611,886
|
)
|
-
|
-
|
(19,418
|
)
|
-
|
-
|
-
|
(19,418
|
)
|
|||||||||||||||||||||
Dividends
|
-
|
-
|
-
|
-
|
-
|
(2,241
|
)
|
-
|
(2,241
|
)
|
||||||||||||||||||||||
Net income
|
-
|
-
|
-
|
-
|
-
|
16,422
|
(445
|
)
|
15,977
|
|||||||||||||||||||||||
Ending balance June 30, 2022
|
17,890,441
|
$
|
198
|
$
|
110,563
|
$
|
(68,287
|
)
|
$
|
(2,064
|
)
|
$
|
85,641
|
$
|
1,880
|
$
|
127,931
|
|||||||||||||||
Beginning balance January 1, 2021
|
19,133,794
|
$
|
195
|
$
|
102,423
|
$
|
(10,191
|
)
|
$
|
(2,635
|
)
|
$
|
23,645
|
$
|
4,050
|
$
|
117,487
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $61
|
- | - | - | - | (192 | ) | - | - | (192 | ) | ||||||||||||||||||||||
Unrealized gain on derivative instruments, net of tax of $810
|
-
|
-
|
-
|
-
|
2,626
|
-
|
-
|
2,626
|
||||||||||||||||||||||||
Foreign currency translation, net of tax of $0
|
- | - | - | - | 480 | - | 480 | 960 | ||||||||||||||||||||||||
Stock compensation expense
|
-
|
-
|
4,263
|
-
|
-
|
-
|
-
|
4,263
|
||||||||||||||||||||||||
Exercise of options
|
83,760
|
1
|
885
|
-
|
-
|
-
|
-
|
886
|
||||||||||||||||||||||||
Redemption of options |
- | - | (2,111 | ) | - | - | - | - | (2,111 | ) | ||||||||||||||||||||||
Cost of repurchased common stock
|
(294,031
|
)
|
-
|
-
|
(14,086
|
)
|
-
|
-
|
-
|
(14,086
|
)
|
|||||||||||||||||||||
Dividends
|
-
|
-
|
-
|
-
|
-
|
(2,135
|
)
|
-
|
(2,135
|
)
|
||||||||||||||||||||||
Net income
|
-
|
-
|
-
|
-
|
-
|
27,137
|
(567
|
)
|
26,570
|
|||||||||||||||||||||||
Ending balance June 30, 2021
|
18,923,523
|
$
|
196
|
$
|
105,460
|
$
|
(24,277
|
)
|
$
|
279
|
$
|
48,647
|
$
|
3,963
|
$
|
134,268
|
The accompanying notes are an integral part of the consolidated financial statements.
Notes to Consolidated Financial Statements
(dollars in thousands, except where designated and per share data)
Note 1. Description of Business and Basis of Presentation
Description of Business
Turning Point Brands, Inc. and its subsidiaries (collectively
referred to herein as the “Company,” “we,” “our,” or “us”) is a leading manufacturer, marketer and distributor of branded consumer products. The Company sells a wide range of products to adult consumers consisting
of staple products with its iconic brands Zig-Zag® and Stoker’s® and its next
generation products to fulfill evolving consumer preferences. The Company’s three focus segments are led by its core, proprietary brands: Zig-Zag® in the Zig-Zag Products segment; Stoker’s® along with Beech-Nut® and Trophy® in the Stoker’s Products segment; and its distribution platforms (Vapor
Beast®, VaporFi® and Direct Vapor®)and Solace® in the NewGen Products segment. The
Company’s products are available in more than 215,000 retail outlets in North America. The
Company operates in three segments: (i) Zig-Zag Products, (ii) Stoker’s Products, and (iii) NewGen Products.
Basis of Presentation
The accompanying unaudited interim, consolidated financial statements have been prepared in accordance with the
accounting practices described in the Company’s audited, consolidated financial statements as of and for the year ended December 31, 2021, included in its Annual Report on Form 10-K for the year then ended. In
the opinion of management, the unaudited, interim, consolidated financial statements included herein contain all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company for the periods
indicated. Such adjustments, other than nonrecurring adjustments separately disclosed, are of a normal and recurring nature. The operating results for interim periods are not necessarily indicative of results to be expected for a full year or
future interim periods. The unaudited, interim, consolidated financial statements should be read in conjunction with the Company’s audited, consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021. The
accompanying interim, consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and, accordingly, do not include all the disclosures required by generally
accepted accounting principles in the United States (“GAAP”) with respect to annual financial statements.
Note 2. Summary of Significant Accounting Policies
Consolidation
The consolidated financial statements include the accounts of the Company, its subsidiaries, all of which are wholly-owned, and variable interest entities (“VIEs”) for
which the Company is considered the primary beneficiary. All significant intercompany transactions have been eliminated.
Revenue Recognition
The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606),
which includes excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns and incentives, upon delivery of goods to the customer – at which time the Company’s performance obligation is
satisfied - at an amount that the Company expects to be entitled to in exchange for those goods in accordance with the five-step analysis outlined in Topic 606: (i) identify the contract with the customer, (ii) identify the performance obligations in
the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. The Company excludes from the transaction price,
sales taxes and value-added taxes imposed at the time of sale (which do not include excise taxes on smokeless tobacco, cigars or vaping products billed to customers).
The Company records an allowance for sales returns, based principally on historical volume and return rates, which is included in accrued
liabilities on the consolidated balance sheets. The Company records sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction in revenues (a portion of which is based on amounts estimated as being due to
wholesalers, retailers and consumers at the end of the period) based principally on historical volume and utilization rates. Expected payments for sales incentives are included in accrued liabilities on the consolidated balance sheets.
A further requirement of ASC 606 is for entities to disaggregate revenue recognized from contracts with customers into categories that depict how
the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The Company’s management views business performance through segments that closely resemble the performance of major product lines. Thus, the
primary and most useful disaggregation of the Company’s contract revenue for decision making purposes is the disaggregation by segment which can be found in Note 17. An additional disaggregation of contract revenue by sales channel can be found
within Note 17 as well.
Shipping Costs
The Company records shipping costs incurred as a component of selling,
general, and administrative expenses. Shipping costs incurred were approximately $6.0 million and $8.1 million for the three months ended June 30, 2022 and 2021, respectively. Shipping costs incurred were approximately $12.1 million and $14.1 million for the
six months ended June 30, 2022 and 2021, respectively.
Inventories
Inventories are stated at the lower of cost or net realizable value using the first-in, first-out (“FIFO”) method. Leaf tobacco is presented in
current assets in accordance with standard industry practice, notwithstanding the fact that such tobaccos are carried longer than one year for the purpose of curing.
Fair Value
GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3).
The three levels of the fair value hierarchy under GAAP are described below:
● |
Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date.
|
● |
Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
|
● |
Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement
date.
|
Derivative Instruments
Foreign Currency Forward Contracts: The Company enters into foreign currency forward contracts to hedge a portion of its exposure to changes in foreign currency exchange rates on inventory purchase commitments. The Company
accounts for its forward contracts under the provisions of ASC 815, Derivatives and Hedging. Under the Company’s policy, the Company may hedge up to 100%
of its anticipated purchases of inventory in the denominated invoice currency over a forward period not to exceed twelve months. The
Company may also, from time to time, hedge up to ninety percent of its non-inventory purchases in the denominated invoice currency.
Forward contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge ineffectiveness which is recognized currently in income. Gains and
losses on these forward contracts are transferred from other comprehensive income into inventory as the related inventories are received and are transferred to net income as inventory is sold. Changes in fair value of any contracts that do not
qualify for hedge accounting or are not designated as hedges are recognized currently in income.
Interest Rate Swap Agreements: The Company enters into interest rate swap contracts to manage interest rate risk and reduce the volatility of future cash flows. The Company accounts for its interest rate swap contracts
under the provisions of ASC 815, Derivatives and Hedging. Swap contracts that qualify as hedges are adjusted to their fair value through other comprehensive income as determined by market prices on the measurement date, except any hedge
ineffectiveness which is recognized currently in income. Gains and losses on these swap contracts are transferred from other comprehensive income into net income upon settlement of the derivative position or at maturity of the interest rate swap
contract. Changes in fair value of any contracts that do not qualify for hedge accounting or are not designated as hedges are recognized currently in income.
Risks and Uncertainties
Manufacturers and sellers of tobacco products are subject to regulation at the federal, state, and local levels. Such regulations include, among
others, labeling requirements, limitations on advertising, and prohibition of sales to minors. The tobacco industry is likely to continue to be heavily regulated. There can be no assurance as to the ultimate content, timing, or effect of any
regulation of tobacco products by any federal, state, or local legislative or regulatory body, nor can there be any assurance that any such legislation or regulation would not have a material adverse effect on the Company’s financial position,
results of operations, or cash flows. In a number of states, targeted flavor bans have been proposed or enacted legislatively or by the administrative process. Depending on the number and location of such bans, that legislation or regulation could
have a material adverse effect on the Company’s financial position, results of operations or cash flows. Food and Drug Administration (“FDA”) continues to consider various restrictive regulations around our products, including targeted flavor bans;
however, the details, timing, and ultimate implementation of such measures remain unclear.
The tobacco industry has experienced, and is experiencing, significant product liability litigation. Most tobacco liability lawsuits have been
brought against manufacturers and sellers of cigarettes for injuries allegedly caused by smoking or exposure to smoke. However, several lawsuits have been brought against manufacturers and sellers of smokeless products for injuries to health
allegedly caused by use of smokeless products. Typically, such claims assert that use of smokeless products is addictive and causes oral cancer. Additionally, several lawsuits have been brought against manufacturers and distributors of NewGen
products due to malfunctioning devices. There can be no assurance the Company will not sustain losses in connection with such lawsuits and that such losses will not have a material adverse effect on the Company’s financial position, results of
operations, or cash flows.
Master Settlement Agreement (MSA): Pursuant to the Master Settlement Agreement (the “MSA”) entered into in November 1998 by most states (represented by their attorneys general acting through the National
Association of Attorneys General) and subsequent states’ statutes, a “cigarette manufacturer” (which is defined to include a manufacturer of make-your-own (“MYO”) cigarette tobacco) has the option of either becoming a signatory to the MSA or
opening, funding, and maintaining an escrow account to have funds available for certain potential tobacco-related liabilities with sub-accounts on behalf of each settling state. Such companies are entitled to direct the investment of the escrowed
funds and withdraw any appreciation but cannot withdraw the principal for twenty-five years from the year of each annual deposit, except to withdraw funds deposited pursuant to an individual state’s escrow statute to pay a final judgement to that state’s plaintiffs in the event
of such a final judgement against the Company. The Company chose to open and fund an escrow account as its method of compliance. It is the Company’s policy to record amounts on deposit in the escrow account for prior years as a non-current asset.
As of June 30, 2022, the Company had on deposit approximately $32.1 million, the fair value of which was approximately $29.2 million. At December 31, 2021, the Company had on deposit approximately $32.1 million, the fair value of which was approximately $31.7
million. The Company discontinued its generic category of MYO in 2019 and its Zig-Zag branded MYO cigarette
smoking tobacco in 2017. Thus, pending a change in MSA legislation, the Company has no remaining product lines covered by the MSA and will not be required to make future escrow deposits.
The Company has chosen to invest a portion of the MSA escrow, from time to time, in U.S. Government securities including TIPS, Treasury Notes, and
Treasury Bonds. These investments are classified as available-for-sale and carried at fair value. Realized losses are prohibited under the MSA; any investment in an unrealized loss position will be held until the value is recovered, or until
maturity.
Fair values for the U.S. Governmental agency obligations are Level 2 in the fair value hierarchy. The following tables show cost and estimated fair
value of the assets held in the MSA account, respectively, as well as the maturities of the U.S. Governmental agency obligations held in such account for the periods indicated.
As of June 30, 2022
|
As of December 31, 2021
|
|||||||||||||||||||||||||||||||
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
|||||||||||||||||||||||||
Cash and cash equivalents
|
$
|
2,035
|
$
|
-
|
$
|
-
|
$
|
2,035
|
$
|
12,155
|
$ | - | $ | - | $ | 12,155 | ||||||||||||||||
U.S. Governmental agency obligations
(unrealized position < 12 months)
|
21,090
|
-
|
(1,772
|
)
|
19,318
|
19,918
|
4 | (357 | ) | 19,565 | ||||||||||||||||||||||
U.S. Governmental agency obligations
(unrealized position > 12 months)
|
8,948 | - | (1,077 | ) | 7,871 | - | - | - | - | |||||||||||||||||||||||
$
|
32,073
|
$
|
-
|
$
|
(2,849
|
)
|
$
|
29,224
|
$
|
32,073
|
$ |
4 | $ |
(357 | ) | $ |
31,720 |
As of
|
||||
June 30, 2022
|
||||
Less than one year
|
$
|
-
|
||
One to five years
|
7,443
|
|||
Five to ten years
|
20,640
|
|||
Greater than ten years
|
1,955
|
|||
Total
|
$
|
30,038
|
The following table shows the amount of deposits by sales year for the MSA escrow account:
|
Deposits as of
|
|||||||
Sales
Year
|
June 30,
2022
|
December 31,
2021
|
||||||
1999
|
$
|
211
|
$
|
211
|
||||
2000
|
1,017
|
1,017
|
||||||
2001
|
1,673
|
1,673
|
||||||
2002
|
2,271
|
2,271
|
||||||
2003
|
4,249
|
4,249
|
||||||
2004
|
3,714
|
3,714
|
||||||
2005
|
4,553
|
4,553
|
||||||
2006
|
3,847
|
3,847
|
||||||
2007
|
4,167
|
4,167
|
||||||
2008
|
3,364
|
3,364
|
||||||
2009
|
1,619
|
1,619
|
||||||
2010
|
406
|
406
|
||||||
2011
|
193
|
193
|
||||||
2012
|
199
|
199
|
||||||
2013
|
173
|
173
|
||||||
2014
|
143
|
143
|
||||||
2015
|
101
|
101
|
||||||
2016
|
91
|
91
|
||||||
2017
|
82
|
82
|
||||||
Total
|
$
|
32,073
|
$
|
32,073
|
Food and Drug Administration (FDA): On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act (the “FSPTCA”) authorized the FDA to immediately regulate the manufacturing, sale, and marketing
of four categories of tobacco products – cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. On August 8, 2016, the FDA deeming regulation became effective. The deeming regulation gave the FDA the authority to also regulate cigars, pipe tobacco, e-cigarettes, vaporizers, and e-liquids as “deemed” tobacco products
under the FSPTCA.
The FDA assesses tobacco product user fees on six classes of regulated tobacco products and computes user fees using a
methodology similar to the methodology used by the U.S Department of Agriculture to compute the Tobacco Transition Payment Program (“TTPP,” also known as the “Tobacco Buyout”) assessment. First, the total, annual, congressionally established user
fee assessment is allocated among the various classes of tobacco products using the federal excise tax weighted market share of tobacco products subject to regulation. Then, the assessment for each class of tobacco products is divided among
individual manufacturers and importers.
In August 2016, the FDA’s regulatory authority under the Tobacco Control Act (the “TCA”) was extended to all tobacco products not previously
covered, including: (i) certain NewGen products (such as electronic cigarettes, vaporizers and e-liquids) and their components or parts (such as tanks, coils and batteries); (ii) cigars and their components or parts (such as cigar tobacco and wraps);
(iii) pipe tobacco; (iv) hookah products; and (v) any other tobacco product “newly deemed” by the FDA. These “deeming regulations” apply to all products made or derived from tobacco intended for human consumption, but excluding accessories of tobacco
products (such as lighters). Accordingly, the FDA has since regulated our cigar and cigar wrap products as well as our vapor products containing tobacco-derived nicotine and products intended or reasonably expected to be used to consume such
e-liquids.
As a result of the deeming regulations, the FDA regulates our cigar and cigar wrap products as well as our vapor products containing tobacco-derived
nicotine and products intended or reasonably expected to be used to consume.
Subsequently, on April 14, 2022, FDA Center for Tobacco Products also obtained jurisdiction over non-tobacco nicotine products (“NTN Products”),
including synthetic nicotine. This law subjects NTN Products to the same requirements as tobacco-derived products, including not selling these products to persons under 21 years of age, not marketing these products as modified risk tobacco products
without authorization, and not distributing free samples of these products. Additionally, NTN Products became subject to premarket filing requirements. Under the new law, manufacturers were required to file a PMTA by May 14, 2022, in order to
continue selling products currently on the market. NTN Products subject of a timely-filed PMTA, and not in receipt of a negative action, were allowed to remain on the market until July 13, 2022, at which time these products became subject to
enforcement, similar to tobacco-derived products remaining under review.
A successful PMTA must demonstrate that the subject product is “appropriate for the protection of public health,” taking into account the effect of
the marketing of the product on all sub-populations while a Substantial Equivalence Report must demonstrate that a new product either has the same characteristics as its predicate product or different characteristics, but does not raise different
questions of public health. We submitted premarket filings prior to the September 9, 2020 deadline for certain of our tobacco and tobacco-derived products, all of which remain under review. We likewise filed premarket submissions for certain of our
NTN Products ahead of the May 14, 2022 deadline. We have continued to supplement these applications with additional information; however, there can be no guarantee that FDA will accept such amendments or that the applications will meet the standard
of “appropriate for the protection of public health.” The FDA has indicated its enforcement priority is those applicants who have received negative action on their application, such as a Marketing Denial Order or Refuse to File notification and who
continue to illegally sell those unauthorized products, as well as products for which manufacturers failed to submit a marketing application. Despite these stated enforcement priorities, given FDA’s limited resources we expect that for a period of
time there may be a lack of enforcement, which may adversely impact our ability to compete in the marketplace against those who continue to sell unauthorized products. There can be no guarantee that FDA will not shift its enforcement priorities or
that it will increase in ability to enforce against unauthorized products over time.
The FDA has issued
a number of proposed rules related to premarket filings; however, those rules were not finalized prior to the September 9, 2020, filing deadline. On October 5, 2021, the FDA finalized two rules related to the Substantial Equivalence process and the PMTA process, respectively, which both became effective November 4, 2021. Both final rules (collectively,
the “Rules”) indicate that any new or additional requirements will not retroactively apply to currently pending PMTAs for tobacco and tobacco-derived products; however, the information outlined in the rule remains important to the FDA’s
substantive review of an application. FDA has yet to indicate how it might apply these Rules to NTN Product filings. We believe we have products that meet the Rules and have filed premarket filings supporting a showing of the respective
required standards. However, there is no assurance that the FDA’s guidance or regulations will not change, that the FDA will not prioritize its enforcement in a manner that negatively affects our pending applications, or that unforeseen
circumstances will not arise that prevent us from sufficiently supplementing or completing our applications or otherwise increase the amount of time and money we are required to spend to receive all necessary marketing orders. Although we filed
many premarket applications in a timely manner, no assurance can be given that the applications will ultimately be successful. This may result in the prioritization of supplementing or completing applications for high priority SKUs in our
inventory position, which could adversely impact future revenues generated by lower priority SKUs.
In addition, we currently distribute many third-party manufactured vapor products for which we will be completely dependent on the manufacturer
complying with the premarket filing requirements. There can be no assurance that these third-party products will receive a marketing order or otherwise remain in compliance with relevant legal requirements. While we will take measures to pursue
regulatory compliance for our own privately-branded or proprietary vape products that compete with these third-party products, there is no assurance that such proprietary products would be as successful in the marketplace or can fully displace
third-party products that are currently being distributed by us, which could adversely affect our results of operations and liquidity. For a period of time after the filing deadline, we expect there to be a lack of enforcement, which may adversely
affect our ability to compete in the marketplace against those who continue to sell unauthorized products.
On May 4, 2022, the FDA proposed two
tobacco product standards related to combusted tobacco products: (1) a ban on menthol as a characterizing flavor in cigarettes; and (2) a ban on all characterizing flavors (including menthol) in cigars. On June 21, 2022, FDA also issued a proposed
product standard related to restricting the level of nicotine in traditional cigarettes. These product standards are required to go through the formal rulemaking process where we would have the opportunity to comment on the proposed rule with regard
to any impact on any of our products. The FDA’s policy on these and other regulated products may change or expand over time in ways not yet known and may significantly impact our products or our premarket filings.
Prevent All Cigarette Trafficking Act (“PACT Act”):
On December 27, 2020,
President Trump signed the Further Consolidated Appropriations Act, 2021, into law. This law included an amendment to the Jenkins Act expanding the definition of “cigarette” to include “electronic nicotine delivery systems,” or ENDS, and required
that the United States Postal Service (USPS) promulgate regulations clarifying the applicability of the prohibition on delivery sales of cigarettes to ENDS. USPS issued its final rule on October 21, 2021. We have received appropriate shipping
exemptions from carrier services we use to carry the affected freight. Failure to comply with the PACT Act could result in significant financial or criminal penalties. To the extent we are unable to respond to, or comply with, these new requirements,
we could lose our shipping exemptions, be subject to civil or criminal penalties, or there could be a material adverse effect on our business, results of operations and financial condition.
Note 3. Acquisitions
Unitabac
In July 2021, the Company acquired certain assets of Unitabac, a marketer of mass-market cigars, for $10.7 million in total consideration, comprised of $9.6
million in cash and $1.1 million of capitalized transaction costs. The acquisition is comprised of a portfolio of cigarillo products and
all related intellectual property, including Cigarillo Non-Tip (“NT”) Homogenized Tobacco Leaf (“HTL”) products and Rolled Leaf and Natural Leaf Cigarillo Products. The transaction was accounted for as an asset purchase with $10.0 million assigned to intellectual property, which has an indefinite life, and $0.7 million assigned to inventory. The intellectual property asset is deductible for tax purposes.
Direct Value Wholesale
In April 2021, Turning Point Brands Canada, a VIE for which the Company is considered the primary beneficiary, purchased 100% of the equity interests of Westhem Ventures LTD d/b/a Direct Value Wholesale (“DVW”) for $3.9 million, net of cash acquired, with $3.5 million paid in cash
at closing and $0.5 million in accrued consideration to be paid during 2021. DVW is a Canadian distribution entity that operates in markets
not primarily served by Turning Point Brands Canada. The acquisition expands Turning Point Brands Canada’s markets in Canada. On April 13, 2021, in connection with the acquisition of DVW, the Company provided a $3.7 million unsecured loan to Turning Point Brands Canada bearing interest at 8% per annum and maturing April 13, 2023. The unsecured loan is eliminated in the consolidation of Turning Point Brands Canada. The following table summarizes the consideration
transferred and calculation of goodwill based on excess of the acquisition price over the estimated fair value of the identifiable net assets acquired:
Total consideration transferred
|
$
|
3,462
|
||
Adjustments to consideration transferred:
|
||||
Cash acquired
|
(43
|
)
|
||
Accrued consideration
|
472
|
|||
Adjusted consideration transferred
|
3,891
|
|||
Assets acquired:
|
||||
Working capital (primarily AR and inventory)
|
1,334
|
|||
Fixed assets and Other long term assets
|
27
|
|||
Net assets acquired
|
$
|
1,361
|
||
Goodwill
|
$
|
2,530
|
The goodwill of $2.5 million
consists of the synergies expected from combining the operations and is deductible for tax purposes.
Turning Point Brands Canada
In July 2021, the Company invested an additional $2.3 million in Turning Point Brands Canada increasing its ownership interest to 65%.
The Company received board seats aligned with its ownership position. The Company has determined that Turning Point Brands Canada continues to be a VIE due to its required subordinated financial support. The Company has determined it remains the
primary beneficiary due to its 65% equity interest, additional subordinated financing and distribution agreement with Turning Point
Brands Canada for the sale of the Company’s products. As a result of the Company remaining the primary beneficiary, the increase in ownership interest resulted in a decrease in Non-controlling interest of $1.1 million and a decrease in Additional paid-in capital of $1.1
million
Note 4. Derivative Instruments
Foreign Currency
The Company’s policy is to manage the risks associated with foreign
exchange rate movements. The policy allows hedging of up to 100% of anticipated purchases of inventory over a forward period that will not exceed 12 rolling and consecutive months. The Company may, from time to time, hedge currency for non-inventory purchases, e.g., production equipment, not to exceed 90% of the purchase price. At June 30, 2022 and December 31, 2021, the Company had no forward contracts outstanding.
Interest Rate Swaps
The Company’s policy is to manage interest rate risk relating to the volatility of future cash flows associated with debt instruments bearing
interest at variable rates. In March 2018, the Company executed various interest rate swap agreements for a notional amount of $70 million
with an expiration of December 2022. The swap agreements fixed LIBOR at 2.755%. The swap agreements met the hedge accounting requirements;
thus, any change in fair value was recorded to other comprehensive income. The Company used the Shortcut Method to account for the swap agreements. The Shortcut Method assumes the hedge to be perfectly effective; thus,
there is no ineffectiveness to be recorded in earnings. The Company terminated the interest rate swap agreement in conjunction with the prepayment of all outstanding amounts under the 2018 First Lien Credit Facility (as defined below) in the first quarter of 2021 with the early termination payment made by the Company in the amount of $3.6 million which was reclassified out of accumulated other comprehensive loss into loss on extinguishment of debt.
Note 5. Fair Value of Financial Instruments
The estimated fair value amounts have been determined by the Company using the methods and assumptions described below. However, considerable
judgment is required to interpret market data to develop estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize in a current market exchange. The use of different
market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.
Cash and Cash Equivalents
Cash and cash equivalents are, by definition, short-term. Thus, the carrying amount is a reasonable estimate of fair value.
Accounts Receivable
The fair value of accounts receivable approximates their carrying value due to their short-term nature.
Long-Term Debt
The Company’s Senior Secured Notes (as defined below) bear interest at a rate of 5.625% per year. As of June 30, 2022, the fair value of the Senior Secured Notes approximated $230.9
million, with a carrying value of $250 million. As of December 31, 2021, the fair value of the Senior Secured Notes approximated their
carrying value of $250 million due to the recency of the notes’ issuance, related to December 31, 2021.
The Convertible Senior Notes (as defined) bear interest at a rate of 2.50% per year, and the fair value of the
Convertible Senior Notes without the conversion feature approximated $147.2 million, with a carrying value of $172.5 million as of June 30, 2022. As of December 31, 2021, the fair value of the Convertible Senior Notes approximated $159.8 million, with a carrying value of $172.5 million.
See Note 11, “Notes Payable and Long-Term Debt”, for further information regarding the Company’s long-term debt.
Note 6. Inventories
The components of inventories are as follows:
|
June 30,
2022
|
December 31,
2021
|
||||||
Raw materials and work in process
|
$
|
7,853
|
$
|
6,936
|
||||
Leaf tobacco
|
49,163
|
35,900
|
||||||
Finished goods - Zig-Zag Products
|
37,435
|
25,663
|
||||||
Finished goods - Stoker’s Products
|
10,798
|
8,959
|
||||||
Finished goods - NewGen products
|
8,379
|
8,591
|
||||||
Other
|
1,501
|
1,558
|
||||||
Inventories
|
$
|
115,129
|
$
|
87,607
|
The inventory valuation allowance was $4.8
million and $7.7 million as of June 30, 2022, and December 31, 2021, respectively.
Note 7. Other Current Assets
Other current assets consist of:
June 30,
2022
|
December 31,
2021
|
|||||||
Inventory deposits
|
$
|
3,223
|
$
|
12,091
|
||||
Insurance deposit
|
3,000
|
3,000
|
||||||
Prepaid taxes |
3,036 |
- |
||||||
Other
|
18,094
|
11,655
|
||||||
Total
|
$
|
27,353
|
$
|
26,746
|
Note 8. Property, Plant, and Equipment
Property, plant, and equipment consists of:
June 30,
2022
|
December 31,
2021
|
|||||||
Land
|
$
|
22
|
$
|
22
|
||||
Buildings and improvements
|
3,096
|
3,096
|
||||||
Leasehold improvements
|
5,391
|
5,374
|
||||||
Machinery and equipment
|
23,927
|
19,591
|
||||||
Furniture and fixtures
|
9,194
|
9,402
|
||||||
Gross property, plant and equipment
|
41,630
|
37,485
|
||||||
Accumulated depreciation
|
(19,254
|
)
|
(18,835
|
)
|
||||
Net property, plant and equipment
|
$
|
22,376
|
$
|
18,650
|
Note 9. Other Assets
Other assets consist of:
|
June 30,
2022
|
December 31,
2021
|
||||||
Equity investments
|
$
|
19,300
|
$
|
25,649
|
||||
Debt security investment | 8,000 | 8,000 |
||||||
Other
|
1,175
|
1,750
|
||||||
Total
|
$
|
28,475
|
$
|
35,399
|
The Company records its equity investments without a readily determinable fair value, that are not accounted for under the equity method, at cost, with adjustments
for impairment and observable price changes.
In June 2022, based on a contemplated sale of the assets of dosist, the Company deemed its investment was impaired resulting in decreasing of the fair value of the
investment to $1.6 million. Fair value was determined using a valuation derived from the contemplated purchase price (Level 3). This
resulted in a loss of $6.3 million which is recorded in investment loss for the three and six months ended June 30, 2022.
In July, 2021, the Company invested $8.0 million in
Old Pal Holding Company LLC (“Old Pal”). The Company invested in the form of a convertible note which includes additional follow-on investment rights. Old Pal is a leading brand in the cannabis lifestyle space that operates a non-plant
touching licensing model. The Company’s investment will enable Old Pal to expand product offerings in existing states, which include California, Nevada, Michigan, Oklahoma, Ohio, Washington and Massachusetts, and will help create the
infrastructure necessary to support continued territory and product expansion. The convertible note bears an interest rate of 3.0%
per year and matures July 31, 2026. Interest and principal are payable at maturity. Old Pal has the option to extend the maturity date in one-year
increments. The interest rate is subject to change based on sales levels of Old Pal meeting certain thresholds. The weighted average interest rate was 3%
for the six months ended June 30, 2022. Old Pal has the option to convert the note into shares once sales reach a certain threshold. Additionally, the Company has the right to convert the note into shares at
any time. The conditions required to allow Old Pal to convert the note were not met as of June 30, 2022. The Company has classified the debt security with Old Pal as available for sale. The Company records the debt security at fair
value and includes unrealized gains and losses recorded in stockholders’ equity as a component of accumulated other comprehensive income on our Consolidated Balance Sheets. The Company reports interest income on available for sale debt
securities, in interest expense, net in our Consolidated Statements of Income. The fair value of the debt security approximated its carrying value of $8.0 million at June 30, 2022 and December 31, 2021, due to the recency of the debt security’s purchase, related to each such
date. The Company has recorded accrued interest receivable of $0.2 million and $0.1 million at June 30, 2022 and December 31, 2021, respectively, in other current assets on
our Consolidated Balance Sheets.
In April 2021, the Company invested
$8.7 million in Docklight Brands, Inc., a pioneering consumer products company with celebrated brands including Marley Natural® cannabis and Marley™ CBD. The Company has additional follow-on investment rights. As part of the investment, the Company obtained exclusive U.S.
distribution rights for Docklight’s Marley™ CBD topical products.
Note 10. Accrued Liabilities
Accrued liabilities consist of:
|
June 30,
2022
|
December 31,
2021
|
||||||
Accrued payroll and related items
|
$
|
5,637
|
$
|
6,974
|
||||
Customer returns and allowances
|
7,759
|
6,497
|
||||||
Taxes payable
|
1,911
|
2,053
|
||||||
Lease liabilities
|
3,068
|
2,976
|
||||||
Accrued interest
|
7,318
|
7,318
|
||||||
Other
|
8,867
|
7,119
|
||||||
Total
|
$
|
34,560
|
$
|
32,937
|
Note 11. Notes Payable and Long-Term Debt
Notes payable and long-term debt consists of the following in order of preference:
June 30,
2022
|
December 31,
2021
|
|||||||
Senior Secured Notes
|
$
|
250,000
|
$
|
250,000
|
||||
Convertible Senior Notes
|
172,500
|
172,500
|
||||||
Gross notes payable and long-term debt
|
422,500
|
422,500
|
||||||
Less deferred finance charges
|
(7,090
|
)
|
(8,328
|
)
|
||||
Notes payable and long-term debt
|
$
|
415,410
|
$
|
414,172
|
Senior Secured Notes
On February 11, 2021, the Company closed a private offering (the “Offering”) of $250 million aggregate principal amount of its 5.625% senior secured notes due
2026 (the “Senior Secured Notes”). The Senior Secured Notes bear interest at a rate of 5.625% and will mature on February 15, 2026. Interest on the Senior Secured Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing on
August 15, 2021.The Company used the proceeds from the Offering (i) to repay all obligations under and terminate the 2018 First Lien Credit Facility, (ii) to pay related fees, costs, and expenses and (iii) for general corporate purposes.
Obligations under the Senior Secured Notes are guaranteed by the Company’s
existing and future wholly-owned domestic subsidiaries (the “Guarantors”) that guarantee any Credit Facility (as defined in the Indenture governing the Senior Secured Notes or the “Senior Secured Notes Indenture”) or capital markets debt
securities of the Company or Guarantors in excess of $15.0 million. The Senior Secured Notes and the related guarantees are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain
exceptions.
The Company may redeem the Senior Secured Notes, in whole or in part, at any time prior to February 15, 2023, at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest, if any, to, but excluding the applicable redemption date, plus a
“make-whole” premium. Thereafter, the Company may redeem the Senior Secured Notes, in whole or in part, at established redemption prices set forth in the Senior Secured Notes Indenture, plus accrued and unpaid interest, if any. In addition, on or
prior to February 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the Senior Secured Notes with the net
cash proceeds from certain equity offerings at a redemption price equal to 105.625%, plus accrued and unpaid interest, if any to the
redemption date; provided, however, that at least 50% of the original
aggregate principal amount of the Senior Secured Notes (calculated after giving effect to the issuance of any additional notes) remains outstanding. In addition, at any time and from time to time prior to February 15, 2023, but not more than once
in any twelve-month period, the Company may redeem up to 10% of the aggregate principal amount of the Senior Secured Notes at a redemption price of 103%
of the aggregate principal amount of Senior Secured Notes redeemed plus accrued and unpaid interest, if any to but not including the redemption date, on the Senior Secured Notes to be redeemed.
If the Company experiences a change of control (as defined in the Senior Secured Notes Indenture), the Company must offer to repurchase the Senior
Secured Notes at a repurchase price equal to 101% of the principal amount of the Notes to be repurchased, plus accrued and unpaid
interest.
The Indenture contains covenants that, among other things, restrict the ability of the Company and its restricted subsidiaries to: (i) grant or
incur liens; (ii) incur, assume or guarantee additional indebtedness; (iii) sell or otherwise dispose of assets, including capital stock of subsidiaries; (iv) make certain investments; (v) pay dividends, make distributions or redeem or repurchase
capital stock; (vi) engage in certain transactions with affiliates; and (vii) consolidate or merge with or into, or sell substantially all of our assets to another entity. These covenants are subject to a number of limitations and exceptions set
forth in the Indenture. The Indenture provides for customary events of default. The Company was in compliance with all covenants as of June 30, 2022.
The Company incurred debt issuance costs attributable to the issuance of the Senior Secured Notes of $6.4 million which are amortized to interest expense using the effective interest method over the expected life of the Senior Secured Notes.
2021 Revolving Credit Facility
In connection with the Offering, the Company also entered into a new $25
million senior secured revolving credit facility (the “2021 Revolving Credit Facility”) with the lenders party thereto (the “Lenders”) and Barclays Bank PLC, as administrative agent and collateral
agent (in such capacity, the “Agent”). The 2021 Revolving Credit Facility provides for a revolving line of credit of up to $25.0 million. Letters of credit are limited to $10 million (and are a part of, and not in addition to, the revolving line of credit). The Company has not drawn any borrowings under the 2021 Revolving Credit Facility but does have letters of credit of approximately $3.6 million outstanding under the facility. The 2021 Revolving Credit Facility will mature on August 11, 2025, if none of the Company’s Convertible Senior Notes are outstanding, and if any
Convertible Senior Notes are outstanding, the date which is 91 days prior
to the maturity date of July 15, 2024, for such Convertible Senior Notes.
Interest is payable on the 2021 Revolving Credit Facility at a fluctuating rate of interest determined by reference to the Eurodollar rate plus an
applicable margin of 3.50% (with step-downs upon de-leveraging). The Company also has the option to borrow at a rate determined by
reference to the base rate.
The obligations under the 2021 Revolving Credit Agreement are guaranteed on a joint and several basis by the Guarantors. The Company’s and
Guarantors’ obligations under the 2021 Revolving Credit Facility are secured on a pari passu basis with the Senior Secured Notes.
The 2021 Revolving Credit Agreement contains covenants that are substantially the same as the covenants in the Senior Secured Notes Indenture. The
2021 Revolving Credit Facility also requires the maintenance of a Consolidated Leverage Ratio (as defined in the 2021 Revolving Credit Agreement) of 5.50
to 1.00 (with a step down to 5.25 to 1.00 beginning with the fiscal quarter ending March 31, 2023) at the end of each fiscal quarter
when extensions of credit under the 2021 Revolving Credit Facility and certain drawn and undrawn letters of credit (excluding (a) letters of credit that have been cash collateralized and (b) letters of credit having an aggregate face amount less
than $5,000,000) in the aggregate outstanding exceeds 35% of the total commitments under the 2021 Revolving Credit Facility. The 2021 Revolving Credit Agreement provides for customary events of default. The
Company was in compliance with all covenants as of June 30, 2022.
The Company incurred debt issuance costs attributable to the issuance of the
2021 Revolving Credit Facility of $0.5 million which
are amortized to interest expense using the effective interest method over the expected life of the 2021 Revolving Credit Facility.
2018 First Lien Credit Facility
The 2018 First Lien Term Loan and the 2018 Revolving Credit Facility bore interest at LIBOR
plus a spread of 2.75% to 3.50%
based on the Company’s senior leverage ratio. The Company used a portion of the proceeds from the issuance of the Senior Secured Notes to prepay all outstanding amounts under and terminate the 2018 First Lien Credit Facility in the first quarter of
2021 in the amount of $130.0 million, and the transaction resulted in a $5.7 million loss on extinguishment of debt.
Convertible Senior Notes
In July 2019, the Company closed an offering of $172.5
million in aggregate principal amount of its 2.50% Convertible Senior Notes due July 15, 2024 (the “Convertible Senior Notes”). The Convertible Senior Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The Convertible Senior Notes will mature on July 15, 2024, unless earlier
repurchased, redeemed or converted. The Convertible Senior Notes are senior unsecured obligations of the Company.
The Convertible Senior Notes are convertible into approximately 3,211,484 shares of TPB Common Stock under certain circumstances prior to maturity at a conversion rate of 18.617 shares per $1,000 principal amount of the Convertible Senior Notes, which
represents a conversion price of approximately $53.71 per share, subject to adjustment under certain conditions, but will not be adjusted
for any accrued and unpaid interest. The conversion price is adjusted periodically as a result of dividends paid by the Company in excess of pre-determined thresholds of $0.04 per share. Upon conversion, the Company may pay cash, shares of common stock or a combination of cash and stock, as determined by the Company at its discretion. The conditions required to
allow the holders to convert their Convertible Senior Notes were not met as of June 30, 2022.
The Company incurred debt issuance costs attributable to the Convertible Senior Notes of $5.9 million which are amortized to interest expense using the effective interest method over the expected life of the Convertible Senior Notes.
In connection with the Convertible Senior Notes offering, the Company entered into privately negotiated capped call transactions with certain
financial institutions. The capped call transactions have a strike price of $53.71 per and a cap price of $82.86 per share, and are exercisable when, and if, the Convertible Senior Notes are converted. The Company paid $20.53 million for these capped calls at the time they were entered into and charged that amount to additional paid-in capital.
Promissory Note
On June 10, 2020, in connection with the acquisition of certain Durfort assets, the Company issued the Promissory Note in the principal amount of $10.0 million, with an annual interest rate of 7.5%, payable quarterly, with the first interest payment due September 10, 2020. The Company prepaid all outstanding amounts under and terminated the Promissory Note in the third quarter of 2021 in the amount of $9.6 million. The transaction resulted in a $0.4 million gain on
extinguishment of debt.
Unsecured Loan
On April 6, 2020, the 2018 First Lien Credit Facility was amended to allow for an unsecured loan under the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES”). On April 17, 2020, National Tobacco Company, L.P., a subsidiary of the Company, entered into a loan agreement with Regions Bank guaranteed by the Small Business Administration for a $7.5 million unsecured loan. The proceeds of the loan were received on April 27, 2020. The loan was scheduled to mature on April 17, 2022 and had a 1.00% interest rate. During 2021, the Company applied for forgiveness for the loan. On October 15, 2021, the Company received notice that its application for forgiveness was fully approved. The extinguishment of the unsecured loan occurred in the fourth quarter of 2021, resulting in a $7.5 million gain on extinguishment of debt. The Company is subject to audit relating to the unsecured loan until 2027
which could result in repayment of some or all of the unsecured loan previously forgiven. However, the Company believes that repayment of any amount is not probable.
Note 12. Leases
The Company’s leases consist primarily of leased property for manufacturing, warehouse and head offices as well as vehicle leases. At lease inception, the Company recognizes a lease right of use asset and lease liability calculated as the present value of future minimum lease payments. In general, the Company does not recognize any renewal
periods within the lease terms as there are no significant barriers to ending the lease at the initial term. Lease and non-lease components are accounted for as a single lease component.
Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for these leases is recognized on a
straight-line basis over the lease term.
The components of lease expense consisted of the following:
Three Months Ended
June 30,
|
||||||||
2022 |
2021 |
|||||||
Operating lease cost
|
||||||||
Cost of sales
|
$
|
233
|
$
|
232
|
||||
Selling, general and administrative
|
683 |
762 |
||||||
Variable lease cost (1)
|
211 |
535 |
||||||
Short-term lease cost
|
11 |
11 |
||||||
Sublease income
|
-
|
(30
|
)
|
|||||
Total
|
$
|
1,138
|
$
|
1,510
|
(1) |
Variable lease cost includes elements of a contract that do
not represent a good or service but for which the lessee is responsible for paying.
|
Six Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Operating lease cost
|
||||||||
Cost of sales
|
$
|
460
|
$
|
457
|
||||
Selling, general and administrative | 1,373 |
1,514 |
||||||
Variable lease cost (1) | 323 |
740 |
||||||
Short-term lease cost | 25 |
22 |
||||||
Sublease income | - | (60 | ) |
|||||
Total | $ | 2,181 |
$ | 2,673 |
(1) |
Variable lease cost includes elements of a contract that do
not represent a good or service but for which the lessee is responsible for paying.
|
June 30,
2022
|
December 31,
2021
|
|||||||
Assets:
|
||||||||
Right of use assets
|
$
|
13,749
|
$
|
15,053
|
||||
Total lease assets
|
$
|
13,749
|
$
|
15,053
|
||||
Liabilities:
|
||||||||
(2) |
$
|
3,068
|
$
|
2,976
|
||||
Long-term lease liabilities
|
11,934 |
13,336 |
||||||
Total lease liabilities
|
$
|
15,002
|
$
|
16,312
|
(2) |
Reported within accrued liabilities on the balance sheet.
|
As of June 30,
|
||||||||
2022
|
2021
|
|||||||
Weighted-average remaining lease term - operating leases
|
6.36 years
|
7.0 years
|
||||||
Weighted-average discount rate - operating leases
|
4.87
|
%
|
4.93
|
%
|
Nearly all the lease contracts for the Company do not provide a readily determinable implicit interest rate. For these contracts, the Company uses a discount rate that approximates its incremental borrowing rate at the time of the lease commencement.
As of June 30, 2022, maturities of lease liabilities consisted of the following:
|
June 30,
2022
|
|||
2022
|
$
|
1,851
|
||
2023
|
3,632
|
|||
2024
|
2,501
|
|||
2025
|
2,187
|
|||
2026
|
2,101
|
|||
Years thereafter
|
5,344
|
|||
Total lease payments
|
$
|
17,616
|
||
Less: Imputed interest
|
2,614
|
|||
Present value of lease liabilities
|
$
|
15,002
|
Note 13. Income Taxes
The Company’s effective income tax rate for the three and six months ended June 30, 2022, was 23.2% and 23.5%, respectively, which includes a discrete tax deduction of $0.3 million
and $0.7 million for the three and six months ended June 30, 2022, respectively, relating to stock option exercises. The Company’s
effective income tax rate for the three and six months ended June 30, 2021, was 22.7% and 21.0%, respectively, which includes a discrete tax deduction
of $2.0 million and $5.2
million for the three and six months ended June 30, 2021, respectively, relating to stock option exercises.
The Company follows the provisions of ASC 740-10-25, which prescribes a recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The amount
recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company has determined that the Company did not have any uncertain tax positions requiring recognition
under the provisions of ASC 740-10-25. The Company’s policy is to recognize interest and penalties accrued on uncertain tax positions, if any, as part of interest expense. The Company files income tax returns in the U.S. federal jurisdiction and
various state jurisdictions. In general, the Company is no longer subject to U.S. federal and state tax examinations for years prior to 2018.
Note 14. Share Incentive Plans
On March 22, 2021, the Company’s Board of Directors adopted the Turning Point Brands, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which awards may be
granted to employees, non-employee directors, and consultants. In addition, the 2021 Plan provides for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2021 Plan, 1,290,000 shares, plus 100,052 shares
remaining available for issuance under the 2015 Equity Incentive Plan (the “2015 Plan”), of TPB Common Stock are reserved for issuance as awards to employees, non-employee directors, and consultants as compensation for past or future services or the
attainment of certain performance goals. The 2021 Plan is scheduled to terminate on March 21, 2031. The 2021 Plan is administered by the compensation committee (the “Committee”) of the Company’s Board of Directors. The Committee determines the
vesting criteria for the awards, with such criteria to be specified in the award agreement. As of June 30, 2022, net of forfeitures, there were 103,340 Restricted Stock Units (“RSUs”), 109,010 options and 17,029 Performance-Based Restricted Stock Units (“PRSUs”) granted under the 2021 Plan. There are 1,160,673 shares available for grant under the 2021 Plan.
On April 28, 2016, the Board of Directors of the Company adopted the 2015 Plan, pursuant to which awards could have been granted to employees,
non-employee directors, and consultants. In addition, the 2015 Plan provided for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2015 Plan, 1,400,000 shares of TPB Common Stock were reserved for issuance as awards to employees, non-employee directors, and consultants as compensation for past
or future services or the attainment of certain performance goals. The 2015 Plan was scheduled to terminate on April 27, 2026. Upon adoption of the 2021 Plan, the 2015 Plan was terminated, and the Company determined no additional grants would be made under the 2015 Plan. However, all awards issued under the 2015 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected. There are no shares available for grant under the 2015 Plan. The 2015 Plan was administrated by the Committee.
On February 8, 2006, the Board of Directors of the Company adopted the 2006 Equity Incentive Plan (the “2006 Plan”) of North Atlantic Holding
Company, Inc., pursuant to which awards may be granted to employees. The 2006 Plan provides for the granting of nonqualified stock options and restricted stock awards to employees. Upon the adoption of the Company’s 2015 Equity Incentive Plan in
connection with its IPO, the Company determined no additional grants would be made under the 2006 Plan. However, all awards issued under the 2006 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected.
There are no shares available for grant under the 2006 Plan.
Stock option activity for the 2006, 2015 and 2021 Plans is summarized below:
Stock
Option
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Grant Date
Fair Value
|
||||||||||
Outstanding, December 31, 2020
|
711,060
|
$
|
19.58
|
$
|
6.42
|
|||||||
Granted
|
119,500
|
50.93
|
13.58
|
|||||||||
Exercised
|
(202,768
|
)
|
10.22
|
6.35
|
||||||||
Forfeited
|
(7,957
|
)
|
33.22
|
9.63
|
||||||||
Outstanding, December 31, 2021
|
619,835
|
28.51
|
8.70
|
|||||||||
Granted
|
114,827
|
30.58
|
10.34
|
|||||||||
Exercised
|
(37,278
|
)
|
12.75
|
4.14
|
||||||||
Forfeited
|
(8,263
|
)
|
31.35
|
8.77
|
||||||||
Outstanding, June 30, 2022
|
689,121
|
$
|
29.67
|
$
|
9.22
|
Under the 2006, 2015 and 2021 Plans, the total intrinsic value of options exercised during the six months ended June 30, 2022 and 2021, was $0.5 million, and $5.3 million,
respectively.
At June 30, 2022, under the 2006 Plan, the exercise price for the 75,945 outstanding options is $3.83 per share, all of which are exercisable. The weighted average of
the remaining lives of the outstanding stock options with an exercise price of $3.83 is approximately 1.94 years. The Company estimates the expected life of these stock options is ten years from the date of grant. For the $3.83 per share options,
the weighted average fair value of options at the date of grant was determined using the Black-Scholes model with the following assumptions a ten-year
life from grant date, a current share price and exercise price of $3.83, a risk-free interest rate of 3.57%, volatility of 40%, and no assumed dividend yield. Based on these assumptions, the fair value of these options is approximately $2.17 per share option granted.
At June 30, 2022, under the 2015 and 2021 Plans, the risk-free interest rate is based on the U.S. Treasury rate for the expected life at the time of
grant. The expected volatility is based on the average long-term historical volatilities of peer companies. We intend to continue to consistently use the same group of publicly traded peer companies to determine expected volatility until sufficient
information regarding volatility of our share price becomes available or until the selected companies are no longer suitable for this purpose. Due to our limited trading history, we are using the simplified method presented by SEC Staff Accounting
Bulletin No. 107 to calculate expected holding periods, which represent the periods of time for which options granted are expected to be outstanding. We will continue to use this method until we have sufficient historical exercise experience to give
us confidence in the reliability of our calculations. The fair values of these options were determined using the Black-Scholes option pricing model.
The following table outlines the assumptions based on the number of options granted under the 2015 Plan.
February 10,
2017
|
May 17,
2017
|
March 7,
2018
|
March 20,
2019
|
October 24,
2019
|
March 18,
2020
|
February 18,
2021
|
May 3,
2021
|
|||||||||||||||||||||||||
Number of options granted
|
40,000
|
93,819
|
98,100
|
155,780
|
25,000
|
155,000
|
100,000
|
12,000
|
||||||||||||||||||||||||
Options outstanding at June 30, 2022
|
20,000
|
45,733
|
58,067
|
141,784
|
25,000
|
94,117
|
94,148
|
12,000
|
||||||||||||||||||||||||
Number exercisable at June 30, 2022
|
20,000
|
45,733
|
58,067
|
141,784
|
25,000
|
61,818
|
39,335
|
4,080
|
||||||||||||||||||||||||
Exercise price
|
$
|
13.00
|
$
|
15.41
|
$
|
21.21
|
$
|
47.58
|
$
|
20.89
|
$
|
14.85
|
$
|
51.75
|
$
|
47.76
|
||||||||||||||||
Remaining lives
|
4.62
|
4.88
|
5.69
|
6.73
|
7.32
|
7.72
|
8.64
|
8.85
|
||||||||||||||||||||||||
Risk free interest rate
|
1.89
|
%
|
1.76
|
%
|
2.65
|
%
|
2.34
|
%
|
1.58
|
%
|
0.79
|
%
|
0.56
|
%
|
0.84
|
%
|
||||||||||||||||
Expected volatility
|
27.44
|
%
|
26.92
|
%
|
28.76
|
%
|
30.95
|
%
|
31.93
|
%
|
35.72
|
%
|
28.69
|
%
|
29.03
|
%
|
||||||||||||||||
Expected life
|
6.000
|
6.000
|
6.000
|
6.000
|
6.000
|
6.000
|
6.000
|
6.000
|
||||||||||||||||||||||||
Dividend yield
|
-
|
-
|
0.83
|
%
|
0.42
|
%
|
0.95
|
%
|
1.49
|
%
|
0.55
|
%
|
0.59
|
%
|
||||||||||||||||||
Fair value at grant date
|
$
|
3.98
|
$
|
4.60
|
$
|
6.37
|
$
|
15.63
|
$
|
6.27
|
$
|
4.41
|
$
|
13.77
|
$
|
13.06
|
The following table outlines the assumptions based on the number of options granted under the 2021 Plan.
|
May 17,
2021
|
March 14,
2022
|
April 29,
2022
|
|||||||||
Number of options granted
|
7,500
|
100,000 | 14,827 | |||||||||
Options outstanding at June 30, 2022
|
7,500
|
100,000 | 14,827 | |||||||||
Number exercisable at June 30, 2022
|
2,550
|
- | - | |||||||||
Exercise price
|
$
|
45.05
|
$ | 30.46 | $ | 31.39 | ||||||
Remaining lives
|
8.88
|
9.71 | 9.84 | |||||||||
Risk free interest rate
|
0.84
|
%
|
2.10 | % | 2.92 | % | ||||||
Expected volatility
|
31.50
|
%
|
35.33 | % | 35.33 | % | ||||||
Expected life
|
6.000
|
6.000 | 6.000 | |||||||||
Dividend yield
|
0.63
|
%
|
1.01 | % | 0.98 | % | ||||||
Fair value at grant date
|
$
|
13.23
|
$ | 10.23 | $ |
11.07 |
The Company has recorded compensation expense related to the options
based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the options on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the options of approximately $0.3 million and $1.4 million for the
three months ended June 30, 2022 and 2021, respectively. The Company recorded compensation expense related to the options of approximately $0.5
million and $1.7 million for the six months ended June 30, 2022 and 2021, respectively. Total unrecognized compensation expense related
to options at June 30, 2022, is $1.3 million, which will be expensed over 2.2 years.
PRSUs are restricted stock units subject to both performance-based and
service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a five-year period. PRSUs will vest on the
measurement date, which is no more than 65 days after the performance
period provided the applicable service and performance conditions are satisfied. As of June 30, 2022, there are 476,347 PRSUs outstanding, all of which are unvested. The following table outlines the PRSUs granted and outstanding as of June 30, 2022.
March 7,
2018
|
March 20,
2019
|
July 19,
2019
|
March 18,
2020
|
December 28,
2020
|
February 18,
2021
|
March 14,
2022
|
||||||||||||||||||||||
Number of PRSUs granted
|
96,000
|
92,500
|
88,582
|
94,000
|
88,169
|
100,000
|
49,996 | |||||||||||||||||||||
PRSUs outstanding at June 30, 2022
|
89,600
|
77,380
|
21,342
|
86,110
|
58,779
|
93,140
|
49,996 | |||||||||||||||||||||
Fair value as of grant date
|
$
|
21.21
|
$
|
47.58
|
$
|
52.15
|
$
|
14.85
|
$
|
46.42
|
$
|
51.75
|
$ | 30.46 | ||||||||||||||
Remaining lives
|
0.50
|
1.50
|
0.50
|
2.50
|
1.50
|
3.50
|
4.50 |
The Company recorded compensation expense related to the PRSUs of
approximately $0.8 million and
$1.3 million in the consolidated statements of income for the three months
ended June 30, 2022 and 2021, respectively, based on the probability of achieving the performance condition. The Company recorded compensation expense related to the PRSUs of
approximately $1.6 million and $2.5
million in the consolidated statements of income for the six months ended June 30, 2022 and 2021, respectively, based on the probability of achieving the performance condition. Total unrecognized compensation expense related to these awards at
June 30, 2022, is $5.5 million which will be expensed over the service periods based on the probability of achieving the performance condition.
The
Company has granted 95,804 RSUs which vest over
to five years. The following table outlines the RSUs granted and outstanding as of June 30, 2022.
July 23,
2021
|
March 14,
2022
|
March 14,
2022
|
April 29,
2022
|
April 29,
2022
|
||||||||||||||||
Number of RSUs granted
|
1,159
|
50,004
|
28,726
|
11,393
|
4,522 | |||||||||||||||
RSUs outstanding at June 30, 2022
|
1,159
|
50,004
|
28,726
|
11,393
|
4,522 | |||||||||||||||
Fair value as of grant date
|
$
|
51.81
|
$
|
30.46
|
$
|
30.46
|
$
|
31.39
|
$ | 31.39 | ||||||||||
Remaining lives
|
0.06
|
4.50
|
2.50
|
0.82
|
4.50 |
The Company has recorded compensation expense related to the RSUs based on the
provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the RSUs on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the RSUs of
approximately $0.4 million and $0.1
million for the three months ended June 30, 2022 and 2021, respectively. The Company recorded compensation expense related to the RSUs of approximately $0.6
million and $0.1 million for the six months ended June 30, 2022 and 2021, respectively. Total unrecognized compensation expense related
to RSUs at June 30, 2022, is $2.5 million, which will be expensed over 3.55 years.
Note 15. Contingencies
On October 9, 2020, a purported stockholder of Turning Point Brands, Inc., Paul-Emile Berteau, filed a complaint in the Delaware Court of Chancery relating to the merger of SDI with a TPB subsidiary pursuant to the Agreement and Plan of Merger and
Reorganization, dated as of April 7, 2020, by and among TPB, SDI and Merger Sub. The complaint purports to assert two derivative counts for breach of fiduciary duty on TPB’s behalf and against the TPB Board of Directors
and certain SDI affiliates. The third count purports to assert a direct claim against TPB and its Board of Directors based on allegations that TPB’s Amended and
Restated Bylaws are inconsistent with TPB’s certificate of incorporation. On October 26, 2020, the TPB Board of Directors adopted Amendment No. 1 to TPB’s Amended and Restated Bylaws, which amended the challenged section of the bylaws. On June 30, 2021, the court granted in part and
denied in part the defendants’ motions to dismiss. Among other things, the court dismissed TPB director H.C. Charles Diao as a defendant in the action and dismissed the third count of the plaintiff’s
complaint as moot. The remaining defendants answered the complaint on August 23, 2021, and continue to litigate. While the Company believes it has good and valid
defenses to the claims, there can be no assurance that the Company will prevail in this case, and it could have a material adverse effect on the Company’s business and results of operations.
Other major tobacco companies are defendants in product liability claims. In
a number of these cases, the amounts of punitive and compensatory damages sought are significant and, if such a claim were brought against the Company, could have a material adverse effect on our business and results of operations. The Company is
subject to several lawsuits alleging personal injuries resulting from malfunctioning vaporizer devices or batteries and may be subject to claims in the future relating to other NewGen products. The Company is still evaluating these claims and the
potential defenses to them. For example, the Company did not design or manufacture the products at issue; rather, the Company was merely the distributor. Nonetheless, there can be no assurance that the Company will prevail in these cases, and they
could have a material adverse effect on the financial position, results of operations, or cash flows of the Company.
We have several subsidiaries engaged in making, distributing, and selling vapor products. As a result of the overall publicity and controversy
surrounding the vapor industry generally, many companies have received informational subpoenas from various regulatory bodies and in some jurisdictions regulatory lawsuits have been filed regarding marketing practices and possible underage sales. We
expect that our subsidiaries will be subject to some such cases and investigative requests. In the acquisition of the vapor businesses, we negotiated financial “hold-backs”, which we have used to defray expenses associated with the information
production and the cost of defending any such lawsuits as well as the franchisee matter. To the extent that litigation becomes necessary, we believe that the subsidiaries have strong factual and legal defenses against claims that they unfairly
marketed vapor products.
We have two franchisor subsidiaries, one
of which no longer has any franchisees. Like many franchise businesses, in the ordinary course of their business, these subsidiaries are from time to time responding parties to arbitration demands brought by franchisees.
We have reached an agreement to arbitrate a claim brought by a former franchisee. This matter relates to the termination of the franchise
agreement by the franchisor for failure to pay franchising fees and our subsequent demand that the franchisee cease using our marks and de-image locations formerly housing the franchises. The franchisee is claiming tortious interference and
conversion. We believe the franchisor’s ultimate termination of the franchise agreement for multiple uncured material defaults by the franchisee was proper. We believe we have good and valid substantive defenses against the claims and intend on
vigorously defending our interests in this matter.
Note 16. Income Per Share
The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations of net income:
|
Three Months Ended June 30,
|
|||||||||||||||||||||||
2022
|
2021
|
|||||||||||||||||||||||
Income
|
Shares
|
Per
Share
|
Income
|
Shares
|
Per
Share
|
|||||||||||||||||||
Basic EPS:
|
||||||||||||||||||||||||
Numerator
|
||||||||||||||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
||||||||||||||||||||
Denominator
|
||||||||||||||||||||||||
Weighted average
|
18,063,259
|
$
|
0.30
|
18,975,522
|
$
|
0.81
|
||||||||||||||||||
Diluted EPS:
|
||||||||||||||||||||||||
Numerator
|
||||||||||||||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
||||||||||||||||||||
Interest expense related to Convertible Senior Notes, net of tax
|
1,054
|
1,054
|
||||||||||||||||||||||
Diluted net income attributable to Turning Point Brands. Inc.
|
$
|
6,478
|
$
|
16,409
|
||||||||||||||||||||
Denominator
|
||||||||||||||||||||||||
Basic weighted average
|
18,063,259
|
18,975,522
|
||||||||||||||||||||||
Convertible Senior Notes
|
3,211,484
|
3,206,637
|
||||||||||||||||||||||
Stock options
|
168,536
|
307,503
|
||||||||||||||||||||||
21,443,279
|
$
|
0.30
|
22,489,662
|
$
|
0.73
|
|
Six
Months Ended June 30,
|
|||||||||||||||||||||||
2022
|
2021
|
|||||||||||||||||||||||
Income
|
Shares
|
Per
Share
|
Income
|
Shares
|
Per
Share
|
|||||||||||||||||||
Basic EPS:
|
||||||||||||||||||||||||
Numerator
|
||||||||||||||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
16,422
|
$
|
27,137
|
||||||||||||||||||||
Denominator
|
||||||||||||||||||||||||
Weighted average
|
18,159,940
|
$
|
0.90
|
19,034,415
|
$
|
1.43
|
||||||||||||||||||
Diluted EPS:
|
||||||||||||||||||||||||
Numerator
|
||||||||||||||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
16,422
|
$
|
27,137
|
||||||||||||||||||||
Interest expense related to Convertible Senior Notes
|
2,108
|
2,108
|
||||||||||||||||||||||
Diluted net income attributable to Turning Point Brands. Inc.
|
$
|
18,530
|
$
|
29,245
|
||||||||||||||||||||
Denominator
|
||||||||||||||||||||||||
Basic weighted average
|
18,159,940
|
19,034,415
|
||||||||||||||||||||||
Convertible Senior Notes
|
3,211,484
|
3,206,637
|
||||||||||||||||||||||
Stock options
|
231,689
|
318,035
|
||||||||||||||||||||||
21,603,113
|
$
|
0.86
|
22,559,087
|
$
|
1.30
|
Note 17. Segment Information
In accordance with ASC 280, Segment Reporting, the Company has three reportable segments: (1) Zig-Zag Products; (2) Stoker’s Products; and (3) NewGen Products. The Zig-Zag Products segment markets and distributes
(a) rolling papers, tubes, and related products; and (b) finished cigars and MYO cigar wraps. The Stoker’s Products segment (a) manufactures and markets moist snuff and (b) contracts for and markets loose leaf chewing tobacco products. The NewGen
Products segment (a) markets and distributes liquid vapor products and certain other products without tobacco and/or nicotine; (b) distributes a wide assortment of products to non-traditional retail outlets via VaporBeast; and (c) markets and
distributes a wide assortment of products to individual consumers via the VaporFi B2C online platform. Products in the Zig-Zag Products and Stoker’s Products segments are distributed primarily through wholesale distributors in the United States
while products in the NewGen Products segment are distributed primarily through e-commerce to non-traditional retail outlets and direct to consumers in the United States. Corporate unallocated includes the costs and assets of the Company not
assigned to one of the three reportable segments such as intercompany transfers, deferred taxes, deferred financing fees, and
investments in subsidiaries. As a result of a change in the Company’s chief operating decision maker (“CODM”), resulting from the hiring of a new Chief Executive Officer in the first quarter of 2022, certain general and administrative costs
previously included to the NewGen Products segment are now included in Corporate unallocated to align with new management and reporting structures in the Company and better reflect how performance is now evaluated and resources are allocated by the
CODM. Amounts in the prior year period have not been adjusted. Had such prior period amounts been adjusted, approximately $1.1 million
and $2.0 million of costs for the three and six months ended June 30, 2021 previously reported in the segment would have been
reported in Corporate unallocated.
The accounting policies of these segments are the same as those of the Company. Corporate costs are not directly charged to the three reportable segments in the ordinary course of operations. The Company evaluates the performance of its segments and allocates resources to them
based on operating income.
The tables below present financial information about reported segments:
Three Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Net sales
|
||||||||
Zig-Zag products
|
$
|
46,226
|
$
|
47,202
|
||||
Stoker’s products
|
33,588
|
33,369
|
||||||
NewGen products
|
23,111
|
42,072
|
||||||
Total
|
$
|
102,925
|
$
|
122,643
|
||||
Gross profit
|
||||||||
Zig-Zag products
|
$
|
26,430
|
$
|
27,743
|
||||
Stoker’s products
|
18,079
|
18,146
|
||||||
NewGen products
|
6,960
|
14,084
|
||||||
Total
|
$
|
51,469
|
$
|
59,973
|
||||
Operating income (loss)
|
||||||||
Zig-Zag products
|
$
|
18,503
|
$
|
21,338
|
||||
Stoker’s products
|
13,378
|
13,826
|
||||||
NewGen products
|
552
|
1,657
|
||||||
Corporate unallocated (1)(2)
|
(14,287
|
)
|
(11,942
|
)
|
||||
Total
|
$
|
18,146
|
$
|
24,879
|
||||
Interest expense, net
|
5,144
|
5,522
|
||||||
Investment income |
6,227 |
(110 | ) | |||||
Income before income taxes
|
$
|
6,775
|
$
|
19,467
|
||||
Capital expenditures
|
||||||||
Zig-Zag products
|
$
|
2,237
|
$
|
98
|
||||
Stoker’s products
|
670
|
1,177
|
||||||
NewGen products
|
-
|
53
|
||||||
Total
|
$
|
2,907
|
$
|
1,328
|
||||
Depreciation and amortization
|
||||||||
Zig-Zag products
|
$
|
93
|
$
|
93
|
||||
Stoker’s products
|
770
|
629
|
||||||
NewGen products
|
472
|
515
|
||||||
Total
|
$
|
1,335
|
$
|
1,237
|
(1) |
Includes corporate costs that are not allocated to any of the three reportable segments.
|
(2) |
Includes
costs related to PMTA of $2.0 million in 2022 and $3.3 milion in 2021.
|
Six
Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Net sales
|
||||||||
Zig-Zag products
|
$
|
91,898
|
$
|
88,206
|
||||
Stoker’s products
|
65,291
|
62,624
|
||||||
NewGen products
|
46,630
|
79,454
|
||||||
Total
|
$
|
203,819
|
$
|
230,284
|
||||
Gross profit
|
||||||||
Zig-Zag products
|
$
|
52,773
|
$
|
52,639
|
||||
Stoker’s products
|
35,765
|
34,038
|
||||||
NewGen products
|
14,725
|
26,557
|
||||||
Total
|
$
|
103,263
|
$
|
113,234
|
||||
Operating income (loss)
|
||||||||
Zig-Zag products
|
$
|
37,240
|
$
|
40,775
|
||||
Stoker’s products
|
26,883
|
26,081
|
||||||
NewGen products
|
1,230
|
3,663
|
||||||
Corporate unallocated (1)(2)
|
(27,978
|
)
|
(21,291
|
)
|
||||
Total
|
$
|
37,375
|
$
|
49,228
|
||||
Interest expense, net
|
10,340
|
10,009
|
||||||
Investment income
|
6,149
|
(135
|
)
|
|||||
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
Income before income taxes
|
$
|
20,886
|
$
|
33,648
|
||||
Capital expenditures
|
||||||||
Zig-Zag products
|
$
|
4,560
|
$
|
98
|
||||
Stoker’s products
|
1,134
|
2,017
|
||||||
NewGen products
|
-
|
55
|
||||||
Total
|
$
|
5,694
|
$
|
2,170
|
||||
Depreciation and amortization
|
||||||||
Zig-Zag products
|
$
|
185
|
$
|
207
|
||||
Stoker’s products
|
1,537
|
1,263
|
||||||
NewGen products
|
947
|
1,030
|
||||||
Total
|
$
|
2,669
|
$
|
2,500
|
(1) |
Includes corporate
costs that are not allocated to any of the three reportable segments.
|
(2) |
Includes costs
related to PMTA of $3.1 million in 2022 and $9.2 million in 2021.
|
|
June 30,
2022
|
December 31,
2021
|
||||||
Assets
|
||||||||
Zig-Zag products
|
$
|
175,509
|
$
|
227,554
|
||||
Stoker’s products
|
232,285
|
142,334
|
||||||
NewGen products
|
58,532
|
72,746
|
||||||
Corporate unallocated (1)
|
137,983
|
158,926
|
||||||
Total
|
$
|
604,309
|
$
|
601,560
|
(1) |
Includes assets not assigned to the three reportable segments. All goodwill has been allocated to the reportable segments.
|
Revenue Disaggregation—Sales Channel
Revenues of the Zig-Zag Products and Stoker’s Products segments are primarily comprised of sales made to wholesalers while NewGen sales are made
business to business and business to consumer, both online and through our corporate retail stores. NewGen net sales are broken out by sales channel below.
|
NewGen Segment
|
|||||||
Three Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Business to Business
|
$
|
17,674
|
$
|
30,715
|
||||
Business to Consumer - Online
|
5,336
|
11,263
|
||||||
Other
|
101
|
94
|
||||||
Total
|
$
|
23,111
|
$
|
42,072
|
|
NewGen Segment
|
|||||||
Six
Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Business to Business
|
$
|
36,798
|
$
|
57,972
|
||||
Business to Consumer - Online
|
9,569
|
21,296
|
||||||
Other
|
263
|
186
|
||||||
Total
|
$
|
46,630
|
$
|
79,454
|
Net Sales—Domestic vs. Foreign
The following table shows a breakdown of consolidated net sales between domestic and foreign customers.
|
Three Months Ended
June 30,
|
|||||||
2022
|
2021
|
|||||||
Domestic
|
$
|
95,442
|
$
|
116,843
|
||||
Foreign
|
7,483
|
5,800
|
||||||
Total
|
$
|
102,925
|
$
|
122,643
|
|
Six
Months Ended
June 30,
|
|||||||
2022
|
2021
|
|||||||
Domestic
|
$
|
189,208
|
$
|
215,911
|
||||
Foreign
|
14,611
|
14,373
|
||||||
Total
|
$
|
203,819
|
$
|
230,284
|
Note 18. Dividends and Share Repurchase
The most recent dividend of $0.06 per
common share was paid on July 8, 2022, to shareholders of record at the close of business on June 17, 2022.
Dividends are considered restricted payments under the Senior Secured Notes Indenture and 2021 Revolving Credit Facility. The Company is generally
permitted to make restricted payments provided that, at the time of payment, or as a result of payment, the Company is not in default on its debt covenants. Additional earnings and market capitalization restrictions limit the aggregate amount of
restricted, quarterly dividends during a fiscal year.
On February 25, 2020, the Company’s Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. On October 25, 2021,
the Board increased the approved share repurchase program by $30.7 million. On February 24, 2022, the Board increased the approve share repurchase program by $24.6 million. The program is subject to the ongoing discretion of the Board. The total number of shares repurchased for the three months ended June 30, 2022, was 301,662
shares for a total cost of $8.8 million and an average price per share of $29.16. $37.0 million
remains available for share repurchases under the program at June 30, 2022.
You should read the following discussion of the historical financial condition and results of operations in conjunction with our historical consolidated financial statements and
accompanying notes, which are included elsewhere in this Quarterly Report on Form 10-Q. In addition, this discussion includes forward-looking statements subject to risks and uncertainties that may result in actual results differing from statements
we make. See “Cautionary Note Regarding Forward-Looking Statements.” Factors that could cause actual results to differ include those risks and uncertainties discussed in “Risk Factors.”
The following discussion relates to the unaudited financial statements of Turning Point Brands, Inc., included elsewhere in this Quarterly Report on Form 10-Q. In this discussion,
unless the context requires otherwise, references to “our Company” “we,” “our,” or “us” refer to Turning Point Brands, Inc., and its consolidated subsidiaries. References to “TPB” refer to Turning Point Brands, Inc., without any of its
subsidiaries. We were incorporated in 2004 under the name North Atlantic Holding Company, Inc. On November 4, 2015, we changed our name to Turning Point Brands, Inc. Many of the amounts and percentages in this discussion have been rounded for
convenience of presentation.
Overview
Turning Point Brands, Inc. (the “Company,” “we,” “our,” or “us”) is a leading manufacturer, marketer and distributor of branded consumer products.
We sell a wide range of products to adult consumers consisting of staple products with our iconic brands Zig-Zag® and Stoker’s® and our next generation products to fulfill evolving consumer preferences. Among other markets, we compete in the alternative smoking accessories and Other Tobacco
Products (“OTP”) industries. The alternative smoking accessories market is a dynamic market experiencing robust secular growth driven by cannabinoid legalization in the U.S. and Canada, and positively evolving consumer perception and acceptance
in North America. The OTP industry, which consists of non-cigarette tobacco products, exhibited mid-single-digit consumer unit growth over the year period ending 2021 as reported by Management Science Associates, Inc. (“MSAi”), a third-party
analytics and information company. Our three focus segments are led by our core, proprietary brands: Zig-Zag® in the Zig-Zag Products segment; Stoker’s® along with Beech-Nut® and Trophy® in the Stoker’s Products segment; and our distribution platforms (Vapor Beast®, VaporFi® and Direct Vapor®) along with Solace® in the NewGen Products segment. Our businesses generate solid cash flows which we use to invest in our business, finance acquisitions, increase brand support, expand our
distribution infrastructure, and strengthen our capital position. We currently ship to approximately 800 distributors with an additional 200 secondary, indirect wholesalers in the U.S. that carry and sell our products. Under the leadership of a
senior management team with extensive experience in the consumer products, alternative smoking accessories and tobacco industries, we have grown and diversified our business through new product launches, category expansions, and acquisitions
while concurrently improving operational efficiency.
We believe there are meaningful opportunities to grow through acquisitions and joint ventures across all product categories. As of December 31, 2021, our products are available in approximately
195,000 U.S. retail locations which, with the addition of retail stores in Canada, brings our total North American retail presence to an estimated 215,000 points of distribution. Our sales team targets widespread distribution to all traditional
retail channels, including convenience stores, and we have a growing e-commerce business.
Products
We operate in three segments: Zig-Zag Products, Stoker’s Products and NewGen Products. In our Zig-Zag Products segment, we principally market and distribute (i) rolling papers, tubes, and related products; and (ii)
finished cigars and make-your-own (“MYO”) cigar wraps. In our Stoker’s Products segment, we (i) manufacture and market moist snuff tobacco (“MST”) and (ii) contract for and market loose leaf chewing tobacco
products. In our NewGen Products segment, we (i) market and distribute liquid vapor products and certain other products without tobacco and/or nicotine; (ii) distribute a wide assortment of products to non-traditional retail via VaporBeast; and
(iii) market and distribute a wide assortment of products to individual consumers via the VaporFi B2C online platform.
Operations
Our core Zig-Zag Products and Stoker’s Products segments primarily generate revenues from the sale of our products to wholesale distributors who, in turn, resell the products to retail operations. Our
acquisition of VaporBeast in 2016 expanded our revenue streams as we began selling directly to non-traditional retail outlets. Our acquisition of IVG in 2018 enhanced our B2C revenue stream with the addition of the Vapor-Fi online platform. The
acquisition of Solace in 2019 provided us with a line of leading liquids and a powerful new product development platform. Our net sales, which include federal excise taxes, consist of gross sales net of cash discounts, returns, and selling and
marketing allowances.
We rely on long-standing relationships with high-quality, established manufacturers to provide the majority of our produced products. More than 80% of our production, as measured by net sales, is
outsourced to suppliers. The remaining production consists primarily of our moist snuff tobacco operations located in Dresden, Tennessee, and Louisville, Kentucky. Our principal operating expenses include the cost of raw materials used to
manufacture the limited number of our products which we produce in-house; the cost of finished products, which are generally purchased goods; federal excise taxes; legal expenses; and compensation expenses, including benefits and costs of salaried
personnel. Our other principal expenses include interest expense and other expenses.
Key Factors Affecting Our Results of Operations
We consider the following to be the key factors affecting our results of operations:
● |
Our ability to further penetrate markets with our existing products;
|
● |
Our ability to introduce new products and product lines that complement our core business;
|
● |
Decreasing interest in some tobacco products among consumers;
|
● |
Marketing and promotional initiatives, which cause variability in our results;
|
● |
General economic conditions, including consumer access to disposable income and other conditions affecting purchasing power such as inflation;
|
● |
Price sensitivity in our end-markets;
|
● |
Cost and increasing regulation of promotional and advertising activities;
|
● |
Cost of complying with regulation, including the “deeming regulation”
|
● |
Increasing and unpredictable regulation of NewGen products;
|
● |
Counterfeit and other illegal products in our end-markets;
|
● |
Currency fluctuations;
|
● |
Our ability to identify attractive acquisition opportunities; and
|
● |
Our ability to successfully integrate acquisitions.
|
Recent Developments
Non-Tobacco Nicotine Included Under Jurisdiction of FDA’s Center for Tobacco Products
New legislation enacted on March 15, 2022, provides authority for the FDA to regulate tobacco products containing nicotine from any source (“NTN Products”). This law took effect April 14, 2022, and
requires NTN Products to comply with applicable requirements under the Federal Food, Drug, and Cosmetic Act, such as not selling to persons under 21 years of age, not marketing these products as modified risk tobacco products without FDA’s
authorization, and not distributing free samples. Additionally, companies with NTN Products in the market between March 15, 2022, and April 14, 2022, were required to file a premarket tobacco application by May 14, 2022. NTN Products subject of a
timely-filed PMTA, and not in receipt of a negative action, were allowed to remain on the market until July 13, 2022, at which time these products became subject to enforcement, similar to tobacco-derived products remaining under review. We
submitted premarket filings for certain of our NTN Products prior to the May 14, 2022, deadline. While these applications remain under review, we will continue to supplement these filings with additional information to support a finding that the
marketing of these products is “appropriate for the protection of public health.”
CLIPPER® Lighters
In February 2022, we entered into an agreement with Flamagas, a renowned lighter manufacturer, for exclusive distribution of CLIPPER® lighters in the United States and Canada.
Final Rule Related to PACT Act Published
On October 21, 2021, the United States Postal Service (“USPS”) published a Final Rule entitled “Treatment of E-Cigarettes in the Mail,” which followed its earlier publication of the Proposed Rule on
February 19, 2021. This Final Rule was required as a result of the inclusion of Division FF, Title VI (Preventing Online Sales of E-Cigarettes to Children or “POSECA”) in the Further Consolidated Appropriations Act, 2021. POSECA, among other
things, expanded the definition of “cigarettes” in the Jenkins Act and Prevent All Cigarette Trafficking (“PACT”) Act to expressly capture “electronic nicotine delivery systems,” i.e., ENDS. Consistent with the Proposed Rule, the Final Rule extends
the existing prohibition on and exceptions to the mailing of “cigarettes” via USPS to ENDS products, other than the Consumer Testing and Public Health exceptions. Specifically, the Final Rule extends the following exceptions to the prohibition on
mailing of ENDS products: the Business/Regulatory Purposes Exception, the Certain Individuals Exception, and the exception for intra-Alaska and intra-Hawaii shipments. We have received certain shipping exemptions from carrier services to carry the
affected freight and have created a supplemental logistical network for those shipments not covered by the exemptions.
Critical Accounting Policies and Uses of Estimates
There have been no material changes to our critical accounting policies and estimates from the information provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included
in our 2021 Annual Report on Form 10-K.
Recent Accounting Pronouncements
There are no recent accounting pronouncements that impact the Company.
Results of Operations
Comparison of the Three Months Ended June 30, 2022, to the Three Months Ended June 30, 2021
The table and discussion set forth below displays our consolidated results of operations (in thousands):
Three Months Ended June 30,
|
||||||||||||
2022
|
2021
|
% Change
|
||||||||||
Consolidated Results of Operations Data:
|
||||||||||||
Net sales
|
||||||||||||
Zig-Zag products
|
$
|
46,226
|
$
|
47,202
|
-2.1
|
%
|
||||||
Stoker's products
|
33,588
|
33,369
|
0.7
|
%
|
||||||||
NewGen products
|
23,111
|
42,072
|
-45.1
|
%
|
||||||||
Total net sales
|
102,925
|
122,643
|
-16.1
|
%
|
||||||||
Cost of sales
|
51,456
|
62,670
|
-17.9
|
%
|
||||||||
Gross profit
|
||||||||||||
Zig-Zag products
|
26,430
|
27,743
|
-4.7
|
%
|
||||||||
Stoker's products
|
18,079
|
18,146
|
-0.4
|
%
|
||||||||
NewGen products
|
6,960
|
14,084
|
-50.6
|
%
|
||||||||
Total gross profit
|
51,469
|
59,973
|
-14.2
|
%
|
||||||||
Selling, general, and administrative expenses
|
33,323
|
35,094
|
-5.0
|
%
|
||||||||
Operating income
|
18,146
|
24,879
|
-27.1
|
%
|
||||||||
Interest expense, net
|
5,144
|
5,522
|
-6.8
|
%
|
||||||||
Investment loss (income)
|
6,227
|
(110
|
)
|
-5760.9
|
%
|
|||||||
Income before income taxes
|
6,775
|
19,467
|
-65.2
|
%
|
||||||||
Income tax expense
|
1,569
|
4,424
|
-64.5
|
%
|
||||||||
Consolidated net income
|
5,206
|
15,043
|
-65.4
|
%
|
||||||||
Net loss attributable to non-controlling interest
|
(218
|
)
|
(312
|
)
|
-30.1
|
%
|
||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
-64.7
|
%
|
Net Sales: For the three months ended June 30, 2022, consolidated net sales decreased to $102.9 million from $122.6 million for the three months ended June 30,
2021, a decrease of $19.7 million or 16.1%. The decrease in net sales was primarily driven by decreased sales volume in the NewGen Products segment.
For the three months ended June 30, 2022, net sales in the Zig-Zag Products segment decreased to $46.2 million from $47.2 million for the three months ended June 30, 2021, a decrease of $1.0 million
or 2.1%. For the three months ended June 30, 2022, volume decreased 2.3% and price/mix increased 0.2%. Our U.S. rolling papers business grew double-digits, primarily through our e-commerce channels. However, these increases were offset by declines
in the cigar wraps business driven partially by a trade inventory reduction during the current period compared with a trade inventory load in the prior year period.
For the three months ended June 30, 2022, net sales in the Stoker’s Products segment increased to $33.6 million from $33.4 million for the three months ended June 30, 2021, an increase of $0.2 million
or 0.7%. For the three months ended June 30, 2022, volume decreased 6.1% and price/mix increased 6.8%. The increase in net sales was driven by mid-single digit growth of Stoker’s® MST. However, this was offset by a decline in loose-leaf chewing tobacco.
For the three months ended June 30, 2022, net sales in the NewGen products segment decreased to $23.1 million from $42.1 million for the three months ended June 30, 2021, a decrease of $19.0 million
or 45.1%. The decrease in net sales was primarily the result of declines in the vape distribution businesses which continues to be impacted by the regulatory environment.
Gross Profit: For the three months ended June 30, 2022, consolidated gross profit decreased to $51.5 million from $60.0 million for the three months ended June
30, 2021, a decrease of $8.5 million or 14.2%. Gross profit as a percentage of revenue increased to 50.0% for the three months ended June 30, 2022, compared to 48.9% for the three months ended June 30, 2021 driven by mix as the NewGen Products
segment which experienced a significant revenue decrease generates lower margins.
For the three months ended June 30, 2022, gross profit in the Zig-Zag Products segment decreased to $26.4 million from $27.7 million for the three months ended June 30, 2021, a decrease of $1.3
million or 4.7%. Gross profit as a percentage of net sales decreased to 57.2% of net sales for the three months ended June 30, 2022, from 58.8% of net sales for the three months ended June 30, 2021, as a result of strong growth in lower gross
margin products.
For the three months ended June 30, 2022, gross profit in the Stoker’s Products segment was flat at $18.1 million. Gross profit as a percentage of net sales decreased to 53.8% of net sales for the
three months ended June 30, 2022, from 54.4% of net sales for the three months ended June 30, 2021, primarily as a result of an inventory write-down of certain FRE nicotine pouch products due to rationalization of the product line ahead of the
regulatory filing deadline for non-tobacco nicotine products in May 2022.
For the three months ended June 30, 2022, gross profit in the NewGen products segment decreased to $7.0 million from $14.1 million for the three months ended June 30, 2021, a decrease of $7.1 million
or 50.6%. Gross profit as a percentage of net sales decreased to 30.1% of net sales for the three months ended June 30, 2022, from 33.5% of net sales for the three months ended June 30, 2021, primarily as a result of product mix and the competitive
environment.
Selling, General, and Administrative Expenses: For the three months ended June 30, 2022, selling, general, and administrative expenses decreased to $33.3
million from $35.1 million for the three months ended June 30, 2021, a decrease of $1.8 million or 5.0%. Selling, general and administrative expenses in the three months ended June 30, 2022, included $1.5 million of stock options, restricted stock
and incentives expense, $0.4 million of transaction expense, $2.0 million of expense related to PMTA, $0.3 million of expense related to corporate restructuring and $0.9 million of consulting expense related to the scoping of the new ERP and CRM
systems. Selling, general and administrative expenses in the three months ended June 30, 2021, included $2.8 million of stock option, restricted stock and incentives expense (including $1.1 million for accelerated vesting of options for a departing
executive), $0.7 million of transaction costs and $0.6 million of expense related to PMTA.
Interest Expense, net: For the three months ended June 30, 2022, interest expense, net decreased to $5.1 million, from $5.5 million for the three months ended
June 30, 2021 as a result of the repayment of the Promissory Note and forgiveness of the Unsecured Loan each discussed in Note 11.
Investment Loss (Income): For the three months ended June 30, 2022, investment loss increased to $6.2 million, compared to $0.1 million of investment income
for the three months ended June 30, 2021, primarily as a result of the $6.3 million impairment of our investment in dosist. See Note 9 Other Assets in the Consolidated Financial Statements for information on the dosist impairment.
Income Tax Expense: Our income tax expense of $1.6 million was 23.2% of income before income taxes for the three months ended
June 30, 2022 and included a discrete tax benefit of $0.3 million relating to stock option exercises. Our effective income tax rate was 22.7% for the three months ended June 30, 2021 and included a
discrete tax benefit $2.0 million relating to stock option exercises.
Net Loss Attributable to Non-Controlling Interest: Net loss attributable to non-controlling interest was $0.2 million for the three months ended June 30, 2022
compared to $0.3 million for the three months ended June 30, 2021.
Net Income Attributable to Turning Point Brands, Inc.: Due to the factors described above, net income attributable to Turning Point Brands, Inc. for the three
months ended June 30, 2022 and 2021, was $5.4 million and $15.4 million, respectively.
Comparison of the Six Months Ended June 30, 2022, to the Six Months Ended June 30, 2021
The table and discussion set forth below displays our consolidated results of operations (in thousands):
Six Months Ended June 30,
|
||||||||||||
2022
|
2021
|
% Change
|
||||||||||
Consolidated Results of Operations Data:
|
||||||||||||
Net sales
|
||||||||||||
Zig-Zag products
|
$
|
91,898
|
$
|
88,206
|
4.2
|
%
|
||||||
Stoker's products
|
65,291
|
62,624
|
4.3
|
%
|
||||||||
NewGen products
|
46,630
|
79,454
|
-41.3
|
%
|
||||||||
Total net sales
|
203,819
|
230,284
|
-11.5
|
%
|
||||||||
Cost of sales
|
100,556
|
117,050
|
-14.1
|
%
|
||||||||
Gross profit
|
||||||||||||
Zig-Zag products
|
52,773
|
52,639
|
0.3
|
%
|
||||||||
Stoker's products
|
35,765
|
34,038
|
5.1
|
%
|
||||||||
NewGen products
|
14,725
|
26,557
|
-44.6
|
%
|
||||||||
Total gross profit
|
103,263
|
113,234
|
-8.8
|
%
|
||||||||
Selling, general, and administrative expenses
|
65,888
|
64,006
|
2.9
|
%
|
||||||||
Operating income
|
37,375
|
49,228
|
-24.1
|
%
|
||||||||
Interest expense, net
|
10,340
|
10,009
|
3.3
|
%
|
||||||||
Investment loss (income)
|
6,149
|
(135
|
)
|
-4654.8
|
%
|
|||||||
Loss on extinguishment of debt
|
-
|
5,706
|
-100.0
|
%
|
||||||||
Income before income taxes
|
20,886
|
33,648
|
-37.9
|
%
|
||||||||
Income tax expense
|
4,909
|
7,078
|
-30.6
|
%
|
||||||||
Consolidated net income
|
15,977
|
26,570
|
-39.9
|
%
|
||||||||
Net loss attributable to non-controlling interest
|
(445
|
)
|
(567
|
)
|
-21.5
|
%
|
||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
16,422
|
$
|
27,137
|
-39.5
|
%
|
Net Sales: For the six months ended June 30, 2022, consolidated net sales decreased to $203.8 million from $230.3 million for the six months ended June 30,
2021, a decrease of $26.5 million or 11.5%. The decrease in net sales was driven by decreased sales volume in the NewGen Products segment.
For the six months ended June 30, 2022, net sales in the Zig-Zag Products segment increased to $91.9 million from $88.2 million for the six months ended June 30, 2021, an increase of $3.7 million or
4.2%. For the six months ended June 30, 2022, volume increased 1.9% and price/mix increased 2.2%. The increase in net sales was driven by double-digit growth in U.S. rolling papers primarily through our e-commerce channels.
For the six months ended June 30, 2022, net sales in the Stoker’s Products segment increased to $65.3 million from $62.6 million for the six months ended June 30, 2021, an increase of $2.7 million or
4.3%. For the six months ended June 30, 2022, volume decreased 3.2% and price/mix increased 7.5%. The increase in net sales was driven by high-single digit growth of Stoker’s® MST.
For the six months ended June 30, 2022, net sales in the NewGen products segment decreased to $46.6 million from $79.5 million for the six months ended June 30, 2021, a decrease of $32.8 million or
41.3%. The decrease in net sales was primarily the result of declines in the vape distribution businesses which continue to be impacted by the regulatory environment.
Gross Profit: For the six months ended June 30, 2022, consolidated gross profit decreased to $103.3 million from $113.2 million for the six months ended June
30, 2021, a decrease of $10.0 million or 8.8%. Gross profit as a percentage of revenue increased to 50.7% for the six months ended June 30, 2022, compared to 49.2% for the six months ended June 30, 2021 driven by increased margin in the Stoker’s
Products segment and mix as the NewGen Products segment generates lower margins.
For the six months ended June 30, 2022, gross profit in the Zig-Zag Products segment increased to $52.8 million from $52.6 million for the six months ended June 30, 2021, an increase of $0.1 million
or 0.3%. Gross profit as a percentage of net sales decreased to 57.4% of net sales for the six months ended June 30, 2022, from 59.7% of net sales for the six months ended June 30, 2021, as a result of strong growth in lower gross margin products.
For the six months ended June 30, 2022, gross profit in the Stoker’s Products segment increased to $35.8 million from $34.0 million for the six months ended June 30, 2022, an increase of $1.7 million
or 5.1%. Gross profit as a percentage of net sales increased to 54.8% of net sales for the six months ended June 30, 2022, from 54.4% of net sales for the six months ended June 30, 2021, primarily as a result of incremental margin contribution of
MST.
For the six months ended June 30, 2022, gross profit in the NewGen products segment decreased to $14.7 million from $26.6 million for the six months ended June 30, 2021, a decrease of $11.8 million or
44.6%. Gross profit as a percentage of net sales decreased to 31.6% of net sales for the six months ended June 30, 2022, from 33.4% of net sales for the six months ended June 30, 2021, as a result of product mix and the competitive environment.
Selling, General, and Administrative Expenses: For the six months ended June 30, 2022, selling, general, and administrative expenses increased to $65.9 million
from $64.0 million for the six months ended June 30, 2021, an increase of $1.9 million or 2.9%. Selling, general and administrative expenses for the six months ended June 30, 2022, included $2.7 million of stock options, restricted stock and
incentives expense, $0.8 million of transaction expense, $3.1 million of expense related to PMTA, $1.6 million of expense related to corporate restructuring and $1.2 million of consulting expense related to the scoping of the new ERP and CRM
systems. Selling, general and administrative expenses in the six months ended June 30, 2021, included $4.3 million of stock option, restricted stock and incentives expense (including $1.1 million for accelerated vesting of options for a departing
executive), $1.3 million of transaction costs and $0.9 million of expense related to PMTA.
Interest Expense, net: For the six months ended June 30, 2022, interest expense, net increased to $10.3 million, from $10.0 million for the six months ended
June 30, 2021 as a result of the increase in the Company’s outstanding debt in February 2021.
Investment Loss (Income): For the six months ended June 30, 2022, investment income increased to $6.1 million, compared to $0.1 million of investment income
for the six months ended June 30, 2021, primarily as a result of $6.3 million impairment of our investment in dosist. See Note 9 Other Assets in the Consolidated Financial Statements for information on the dosist impairment.
Loss on Extinguishment of Debt: There was no loss on extinguishment of debt for the six months ended June 30, 2022 compared to $5.7 million for the six months
ended June 30, 2021 related to the repayment of the 2018 First Lien Credit Facility.
Income Tax Expense: Our income tax expense of $4.9 million was 23.5% of income before income taxes for the six months ended June
30, 2022 and included a discrete tax benefit of $0.7 million relating to stock option exercises. Our effective income tax rate was 21.0% for the six months ended June 30, 2021 and included a discrete
tax benefit $5.2 million relating to stock option exercises.
Net Loss Attributable to Non-Controlling Interest: Net loss attributable to non-controlling interest was $0.4 million for the six months ended June 30, 2022
compared to $0.6 million for the six months ended June 30, 2021.
Net Income Attributable to Turning Point Brands, Inc.: Due to the factors described above, net income attributable to Turning Point Brands, Inc. for the six
months ended June 30, 2022 and 2021, was $16.4 million and $27.1 million, respectively.
EBITDA and Adjusted EBITDA
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures including EBITDA and Adjusted
EBITDA. We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA is used by management to
compare our performance to that of prior periods for trend analyses and planning purposes and is presented to our Board of Directors. We believe that EBITDA and Adjusted EBITDA are appropriate measures of operating performance because they
eliminate the impact of expenses that do not relate to operating performance. In addition, our debt instruments contain covenants which use Adjusted EBITDA calculations.
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, and amortization. We define “Adjusted EBITDA” as net income before interest expense,
loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items, and other items we do not consider ordinary course in our evaluation of ongoing operating performance noted in the reconciliation below.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Adjusted EBITDA excludes significant expenses required to be recorded in
our financial statements by U.S. GAAP and is subject to inherent limitations. Other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative
measure. The tables below provide reconciliations between net income and Adjusted EBITDA.
(in thousands)
|
Three Months Ended
June 30, |
|||||||
2022
|
2021
|
|||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
||||
Add:
|
||||||||
Interest expense, net
|
5,144
|
5,522
|
||||||
Income tax expense
|
1,569
|
4,424
|
||||||
Depreciation expense
|
879
|
758
|
||||||
Amortization expense
|
456
|
479
|
||||||
EBITDA
|
$
|
13,472
|
$
|
26,538
|
||||
Components of Adjusted EBITDA
|
||||||||
Corporate restructuring (a)
|
270
|
-
|
||||||
ERP/CRM (b)
|
861
|
-
|
||||||
Stock options, restricted stock, and incentives expense (c)
|
1,502
|
2,764
|
||||||
Transactional expenses (d)
|
364
|
702
|
||||||
FDA PMTA (e)
|
1,957
|
-
|
||||||
Non-cash asset impairment (f)
|
6,300
|
-
|
||||||
Adjusted EBITDA
|
$
|
24,726
|
$
|
30,004
|
(a)
|
Represents costs associated with corporate restructuring, including severance.
|
(b)
|
Represents cost associated with scoping new ERP and CRM systems.
|
(c)
|
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.
|
(d)
|
Represents the fees incurred for transaction expenses.
|
(e)
|
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
(f)
|
Represents impairment of investment in dosist.
|
(in thousands)
|
Six Months Ended
June 30, |
|||||||
2022
|
2021
|
|||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
16,422
|
$
|
27,137
|
||||
Add:
|
||||||||
Interest expense, net
|
10,340
|
10,009
|
||||||
Loss on extinguishment of debt
|
-
|
5,706
|
||||||
Income tax expense
|
4,909
|
7,078
|
||||||
Depreciation expense
|
1,750
|
1,546
|
||||||
Amortization expense
|
919
|
954
|
||||||
EBITDA
|
$
|
34,340
|
$
|
52,430
|
||||
Components of Adjusted EBITDA
|
||||||||
Corporate restructuring (a)
|
1,602
|
-
|
||||||
ERP/CRM (b)
|
1,191
|
-
|
||||||
Stock options, restricted stock, and incentives expense (c)
|
2,661
|
4,263
|
||||||
Transactional expenses (d)
|
789
|
1,309
|
||||||
FDA PMTA (e)
|
3,096
|
-
|
||||||
Non-cash asset impairment (f)
|
6,300
|
-
|
||||||
Adjusted EBITDA
|
$
|
49,979
|
$
|
58,002
|
(a)
|
Represents costs associated with corporate restructuring, including severance.
|
(b)
|
Represents cost associated with scoping new ERP and CRM systems.
|
(c)
|
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.
|
(d)
|
Represents the fees incurred for transaction expenses.
|
(e)
|
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
(f)
|
Represents impairment of investment in dosist.
|
Liquidity and Capital Reserves
Our principal uses for cash are working capital, debt service, and capital expenditures. We believe our cash on hand, cash flows from operations and borrowing availability under our 2021 Revolving
Credit Facility are adequate to satisfy our operating cash requirements for the foreseeable future. As of June 30, 2022, we had $107.4 million of cash on hand and have $21.4 million of availability under the 2021 Revolving Credit Facility.
Our working capital, which we define as current assets less cash and current liabilities, increased $22.1 million to $102.6 million at June 30, 2022, compared with $80.5 million at December 31, 2021
primarily due to increase in inventory as a result of our annual tobacco purchase.
As of
|
||||||||
(in thousands)
|
June 30,
|
December 31,
|
||||||
2022
|
2021
|
|||||||
Current assets
|
$
|
151,659
|
$
|
120,849
|
||||
Current liabilities
|
49,034
|
40,336
|
||||||
Working capital
|
$
|
102,625
|
$
|
80,513
|
Cash Flows from Operating Activities
For the six months ended June 30, 2022, net cash provided by operating activities was $7.1 million compared to net cash provided by operating
activities of $37.4 million for the six months ended June 30, 2021, a decrease of $30.3 million, primarily due to lower net income due to decreased sales combined with the timing of changes to working
capital, primarily as a result of annual tobacco inventory purchase.
Cash Flows from Investing Activities
For the six months ended June 30, 2022, net cash used in investing activities was $15.7 million compared to net cash used in investing activities of
$34.4 million for the six months ended June 30, 2021, a decrease of $18.7 million, primarily due to the lower purchases of investments in our MSA escrow account as well as no acquisitions or investments made
in the current year period.
Cash Flows from Financing Activities
For the six months ended June 30, 2022, net cash used in financing activities was $22.5 million compared to net cash provided by financing
activities of $92.2 million for the six months ended June 30, 2021, a decrease of $114.7 million, primarily due to the increase in repurchases of common stock during 2022 compared to net proceeds received
from the Senior Secured Notes partially offset by the repayment in full of the 2018 First Lien Term Loan in the first quarter of 2021.
Dividends and Share Repurchase
The most recent dividend of $0.06 per common share was paid on July 8, 2022, to shareholders of record at the close of business on June 17, 2022.
On February 25, 2020, our Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. On October 25,
2021, the Board increased the approved share repurchase program by $30.7 million. On February 24, 2022, the Board increased the approve share repurchase program by $24.6 million. The program is subject to the ongoing discretion of the Board. The
total number of shares repurchased for the three months ended June 30, 2022, was 301,662 shares for a total cost of $8.8 million and an average price per share of $29.16. $37.0 million remains available for share repurchases under the program at
June 30, 2022.
Long-Term Debt
As of June 30, 2022, we were in compliance with the financial and restrictive covenants of the Senior Secured Notes and 2021 Revolving Credit Facility. The following table provides outstanding
balances of our debt instruments.
June 30,
2022
|
December 31,
2021
|
|||||||
Senior Secured Notes
|
$
|
250,000
|
$
|
250,000
|
||||
Convertible Senior Notes
|
172,500
|
172,500
|
||||||
Gross notes payable and long-term debt
|
422,500
|
422,500
|
||||||
Less deferred finance charges
|
(7,090
|
)
|
(8,328
|
)
|
||||
Notes payable and long-term debt
|
$
|
415,410
|
$
|
414,172
|
Senior Secured Notes
On February 11, 2021, we closed a private offering (the “Offering”) of $250 million aggregate principal amount of our 5.625% senior secured notes due 2026 (the “Senior Secured Notes”). The Senior
Secured Notes bear interest at a rate of 5.625% and will mature on February 15, 2026. Interest on the Senior Secured Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2021.We used the
proceeds from the Offering (i) to repay all obligations under and terminate the 2018 First Lien Credit Facility, (ii) to pay related fees, costs, and expenses and (iii) for general corporate purposes.
Obligations under the Senior Secured Notes are guaranteed by the Company’s existing and future wholly-owned domestic subsidiaries (the “Guarantors”) that guarantee any Credit Facility (as defined in
the Indenture governing the Senior Secured Notes or the “Senior Secured Notes Indenture”) or capital markets debt securities of the Company or Guarantors in excess of $15.0 million. The Senior Secured Notes and the related guarantees are secured
by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.
We may redeem the Senior Secured Notes, in whole or in part, at any time prior to February 15, 2023, at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid
interest, if any, to, but excluding the applicable redemption date, plus a “make-whole” premium. Thereafter, we may redeem the Senior Secured Notes, in whole or in part, at established redemption prices set forth in the Senior Secured Notes
Indenture, plus accrued and unpaid interest, if any. In addition, on or prior to February 15, 2023, we may redeem up to 40% of the aggregate principal amount of the Senior Secured Notes with the net cash proceeds from certain equity offerings at
a redemption price equal to 105.625%, plus accrued and unpaid interest, if any to the redemption date; provided, however, that at least 50% of the original aggregate principal amount of the Senior Secured
Notes (calculated after giving effect to the issuance of any additional notes) remains outstanding. In addition, at any time and from time to time prior to February 15, 2023, but not more than once in any twelve-month period, we may redeem up to
10% of the aggregate principal amount of the Senior Secured Notes at a redemption price of 103% of the aggregate principal amount of Senior Secured Notes redeemed plus accrued and unpaid interest, if any to but not including the redemption date,
on the Senior Secured Notes to be redeemed.
If we experience a change of control (as defined in the Senior Secured Notes Indenture), we must offer to repurchase the Senior Secured Notes at a repurchase price equal to 101% of the principal
amount of the Notes to be repurchased, plus accrued and unpaid interest.
The Indenture contains covenants that, among other things, restrict the ability of the Company and its restricted subsidiaries to: (i) grant or incur liens; (ii) incur, assume or guarantee
additional indebtedness; (iii) sell or otherwise dispose of assets, including capital stock of subsidiaries; (iv) make certain investments; (v) pay dividends, make distributions or redeem or repurchase capital stock; (vi) engage in certain
transactions with affiliates; and (vii) consolidate or merge with or into, or sell substantially all of our assets to another entity. These covenants are subject to a number of limitations and exceptions set forth in the Indenture. The Indenture
provides for customary events of default. We were in compliance with all covenants as of June 30, 2022.
We incurred debt issuance costs attributable to the issuance of the Senior Secured Notes of $6.4 million which are amortized to interest expense using the effective interest method over the expected
life of the Senior Secured Notes.
2021 Revolving Credit Facility
In connection with the Offering, we also entered into a new $25.0 million senior secured revolving credit facility (the “2021 Revolving Credit Facility”) with the lenders party thereto
(the “Lenders”) and Barclays Bank PLC, as administrative agent and collateral agent (in such capacity, the “Agent”). The 2021 Revolving Credit Facility provides for a revolving line of credit of up to $25.0 million. Letters of credit are
limited to $10 million (and are a part of, and not in addition to, the revolving line of credit). We have not drawn any borrowings under the 2021 Revolving Credit Facility but do have letters of credit of approximately $3.6 million outstanding
under the facility. The 2021 Revolving Credit Facility will mature on August 11, 2025 if none of our Convertible Senior Notes are outstanding, and if any Convertible Senior Notes are outstanding, the date which is 91 days prior to the maturity
date of July 15, 2024, for such Convertible Senior Notes.
Interest is payable on the 2021 Revolving Credit Facility at a fluctuating rate of interest determined by reference to the Eurodollar rate plus an applicable margin of 3.50% (with step-downs upon
de-leveraging). We also have the option to borrow at a rate determined by reference to the base rate.
The obligations under the 2021 Revolving Credit Agreement are guaranteed on a joint and several basis by the Guarantors. The Company’s and Guarantors’ obligations under the 2021 Revolving Credit
Facility are secured on a pari passu basis with the Senior Secured Notes.
The 2021 Revolving Credit Agreement contains covenants that are substantially the same as the covenants in the Senior Secured Notes Indenture. The 2021 Revolving Credit Facility also requires the
maintenance of a Consolidated Leverage Ratio (as defined in the 2021 Revolving Credit Agreement) of 5.50 to 1.00 (with a step down to 5.25 to 1.00 beginning with the fiscal quarter ending March 31, 2023) at the end of each fiscal quarter when
extensions of credit under the 2021 Revolving Credit Facility and certain drawn and undrawn letters of credit (excluding (a) letters of credit that have been cash collateralized and (b) letters of credit having an aggregate face amount less than
$5,000,000) in the aggregate outstanding exceeds 35% of the total commitments under the 2021 Revolving Credit Facility. The 2021 Revolving Credit Agreement provides for customary events of default. We were in compliance with all covenants as of
June 30, 2022.
We incurred debt issuance costs attributable to the issuance of the 2021 Revolving Credit Facility of $0.5 million which are amortized to interest expense using the effective interest method over
the expected life of the 2021 Revolving Credit Facility.
2018 Credit Facility
In the first quarter of 2021, we used a portion of the proceeds from the issuance of the Senior Secured Notes to prepay all outstanding amounts under and terminate the 2018 First Lien Credit Facility in the amount of
$130.0 million, and the transaction resulted in a $5.7 million loss on extinguishment of debt. See Note 11, “Notes Payable and Long-Term Debt,” in the Notes to Consolidated Financial Statements included in this
Quarterly Report for further discussion.
Convertible Senior Notes
In July 2019 we closed an offering of $172.5 million in aggregate principal amount of our 2.50% Convertible Senior Notes due July 15, 2024 (the “Convertible Senior Notes”). The Convertible Senior
Notes bear interest at a rate of 2.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The Convertible Senior Notes will mature on July 15, 2024, unless earlier repurchased, redeemed
or converted. The Convertible Senior Notes are senior unsecured obligations.
The Convertible Senior Notes are convertible into approximately 3,211,484 shares of our voting common stock under certain circumstances prior to maturity at a conversion rate of 18.617 shares per
$1,000 principal amount of the Convertible Senior Notes, which represents a conversion price of approximately $53.71 per share, subject to adjustment under certain conditions, but will not be adjusted for any accrued and unpaid interest. The
conversion price is adjusted periodically as a result of dividends paid by the us in excess of pre-determined thresholds of $0.04 per share. Upon conversion, we may pay cash, shares of our common stock or a combination of cash and stock, as
determined by us at our discretion. The conditions required to allow the holders to convert their Convertible Senior Notes were not met as of June 30, 2022.
We incurred debt issuance costs attributable to the Convertible Senior Notes of $5.9 million which are amortized to the interest expense using the effective interest method over the expected life of
the Convertible Senior Notes.
In connection with the Convertible Senior Notes offering, we entered into privately negotiated capped call transactions with certain financial institutions. The capped call transactions have a strike
price of $53.71 per and a cap price of $82.86 per share, and are exercisable when, and if, the Convertible Senior Notes are converted. We paid $20.53 million for these capped calls at the time they were entered into and charged that amount to
additional paid-in capital.
Promissory Note
On June 10, 2020, in connection with the acquisition of certain Durfort assets, we issued an unsecured subordinated promissory note (“Promissory Note”) in the principal amount of $10.0
million (the “Principal Amount”), with an annual interest rate of 7.5%, payable quarterly, with the first interest payment due September 10, 2020. We prepaid all outstanding amounts under and terminated the Promissory Note in the third
quarter of 2021 in the amount of $9.6 million. The transaction resulted in a $0.4 million gain on extinguishment of debt.
Unsecured Loan
On April 17, 2020, National Tobacco Company, L.P., a wholly-owned subsidiary of the Company, entered into a loan agreement with Regions Bank guaranteed by the Small Business
Administration for a $7.5 million unsecured loan issued pursuant to the CARES Act. The proceeds of the loan were received on April 27, 2020. The loan was scheduled to mature on April 17, 2022 and had a 1.00% interest rate. Under the CARES Act we
were permitted to apply for forgiveness of the loan if the proceeds were used as required for certain purposes. During 2021, we applied for forgiveness for the loan. On October 15, 2021, we received notice that our application for forgiveness was
fully approved. The extinguishment of the unsecured loan occurred in the fourth quarter of 2021 resulting in a $7.5 million gain on extinguishment of debt. We are subject to audit relating to the unsecured
loan until 2027 which could result in repayment of some or all of the unsecured loan previously forgiven. However, we believe that repayment of any amount is not probable.
Off-balance Sheet Arrangements
During the three months ended June 30, 2022, the Company did not execute any forward contracts. We had no forward contracts at June 30, 2022. During
2021, we did not execute any forward contracts. We had no forward contracts at December 31, 2021. The Company had no interest rate swap contracts at June 30, 2022. The Company terminated its interest rate swap agreement in conjunction
with the prepayment of all outstanding amounts under to the 2018 First Lien Credit Facility in the first quarter of 2021 in the amount of $3.6 million, and the transaction resulted in a $5.7 million loss recorded in the loss on extinguishment of
debt. See Note 11, “Notes Payable and Long-Term Debt,” in the Notes to Consolidated Financial Statements included in this Quarterly Report for further discussion.
Inflation
Inflation in general and the recent rapid increases in costs of goods and services, such as food and gas prices have had a substantial negative effect on the purchasing power of consumers. While
historically, we have been able to pass on most cost increases to our customers, no assurance can be given that we will continue to be able to do so. In addition, we have been able to maintain a relatively stable variable cost structure for our
products due, in part, to our successful procurement with regard to our tobacco products and, in part, to our existing contractual agreement for the purchase of our premium cigarette papers.
Foreign Currency Sensitivity
There have been no material changes in our exposure to exchange rate fluctuation risk, as reported within our 2021 Annual Report on Form 10-K, during the period. Please refer to our ‘Quantitative and Qualitative
Disclosures about Market Risk’ included in our 2021 Annual Report on Form 10-K filed with the SEC.
Credit Risk
There have been no material changes in our exposure to credit risk, as reported within our 2021 Annual Report on Form 10-K, during the six months ended June 30, 2022. Please
refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2021 Annual Report on Form 10-K filed with the SEC.
Interest Rate Sensitivity
In February 2021, we issued the Senior Secured Notes in an aggregate principal amount of $250 million. In July 2019, we issued Convertible Senior Notes in an aggregate principal amount of $172.5
million. Since the Senior Secured Notes and Convertible Senior Notes bear interest at a fixed rate, we have no financial risk associated with changes in interest rates. However, the fair value of the Convertible Senior Notes changes when the market
price of our stock fluctuates, or interest rates change. Our remaining debt instruments bear interest at fixed rates and are not subject to interest rate volatility.
We have carried out an evaluation under the supervision, and with the participation of, our management including our Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), and Chief Accounting Officer
(“CAO”), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the “Act”)) as of June 30,
2022. Based upon the evaluation, our CEO, CFO, and CAO concluded our disclosure controls and procedures are not effective as of such date solely due to the material weakness in internal controls over financial reporting that was disclosed
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
There have been no changes in the Company’s internal control over financial reporting during the fiscal quarter ended June 30, 2022 which have materially affected, or are reasonably likely to materially affect, the
Company’s internal control over financial reporting.
As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, we began implementing a remediation plan to address the material weakness mentioned above.
The material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time, and management has concluded through testing that these controls are operating effectively. We expect that the
remediation of this material weakness will be completed by the end of the fiscal year 2022.
PART II—OTHER INFORMATION
For a description of our material pending legal proceedings, please see Contingencies in Note 15 to the Notes to the Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report.
See ‘Risk Factors—We may become subject to significant product liability litigation’ within our 2021 Annual Report on Form 10-K for additional details.
In addition to the other information set forth in this report, carefully consider the factors discussed in the ‘Risk Factors’ section contained in our 2021 Annual Report on Form 10-K. There have been
no material changes to the Risk Factors set forth in the 2021 Annual Report on Form 10-K.
On February 25, 2020, the Company’s Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. On
October 25, 2021, the Board increased the approved share repurchase program by $30.7 million bringing the authority at the time back to $50 million (including approximately $19.3 million available for repurchases under the Board’s previous
authorization). On February 24, 2022, the Board increased the approved share repurchase program by $24.6 million bringing total authority at that time to $50 million. This share repurchase program has no expiration date and is subject to the
ongoing discretion of the Board. All repurchases to date under our stock repurchase programs have been made through open market transactions, but in the future, we may also purchase shares through privately negotiated transactions or 10b5-1
repurchase plans.
The following table includes information regarding purchases of our common stock made by us during the quarter ended June 30, 2022 in connection with the repurchase program described above:
Period
|
Total Number
of Shares
Purchased (1)
|
Average
Price Paid
per Share
|
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
|
Maximum Number
(or Approximate
Dollar Value)
of Shares that
May Yet Be
Purchased Under the
Plans or Programs
|
||||||||||||
April 1 to April 30
|
74,071
|
$
|
31.88
|
74,071
|
$
|
43,439,027
|
||||||||||
May 1 to May 31
|
90,721
|
$
|
29.05
|
83,002
|
$
|
41,045,250
|
||||||||||
June 1 to June 30
|
144,589
|
$
|
27.95
|
144,589
|
$
|
37,003,987
|
||||||||||
Total
|
309,381
|
301,662
|
(1) The total number of shares purchased includes (a) shares purchased under the February 2020 share repurchase program (which totaled
74,071 shares in April, 83,002 in May and 144,589 shares in June) and (b) shares withheld by the Company in an amount equal to the statutory withholding taxes for holders who vested in stock-based awards (which totaled 7,719 shares in May). Shares
withheld by the Company to cover statutory withholdings taxes are repurchased pursuant to the applicable plan and not the authorization under the share repurchase program.
Not applicable.
Not applicable.
None
Exhibit No.
|
Description
|
Rule 13a-14(a)/15d-14(a) Certification of Yavor Efremov.*
|
|
Rule 13a-14(a)/15d-14(a) Certification of Luis Reformina.*
|
|
Rule 13a-14(a)/15d-14(a) Certification of Brian Wigginton.*
|
|
Section 1350 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
|
|
101
|
XBRL (eXtensible Business Reporting Language). The following materials from Turning Point Brands, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on July 27,
2022, formatted in Inline XBRL (iXBRL): (i) consolidated balance sheets, (ii) consolidated statements of income, (iii) consolidated statements of comprehensive income, (iv) consolidated statements of cash flows, and (v) the notes to
consolidated financial statements.*
|
104
|
Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101).*
|
* |
Filed or furnished herewith
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
TURNING POINT BRANDS, INC.
|
|||
By: /s/ Yavor Efremov
|
|||
Name: Yavor Efremov
|
|||
Title: President and Chief Executive Officer
|
|||
By: /s/ Luis Reformina
|
|||
Name: Luis Reformina
|
|||
Title: Chief Financial Officer
|
|||
By: /s/ Brian Wigginton
|
|||
Name: Brian Wigginton
|
|||
Title: Chief Accounting Officer
|
|||
Date: July 27, 2022
|
51